bdpt_10q.htm

0001640334-23-001531.txt : 20230811 0001640334-23-001531.hdr.sgml : 20230811 20230811161640 ACCESSION NUMBER: 0001640334-23-001531 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOADAPTIVES, INC. CENTRAL INDEX KEY: 0001575142 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462592228 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54949 FILM NUMBER: 231164348 BUSINESS ADDRESS: STREET 1: 2620 REGATTA DRIVE STREET 2: SUITE 102 CITY: LAS VEGAS STATE: NV ZIP: 89128 BUSINESS PHONE: (702) 659-8829 MAIL ADDRESS: STREET 1: 2620 REGATTA DRIVE STREET 2: SUITE 102 CITY: LAS VEGAS STATE: NV ZIP: 89128 FORMER COMPANY: FORMER CONFORMED NAME: APEX 8 Inc. DATE OF NAME CHANGE: 20130424 10-Q 1 bdpt_10q.htm FORM 10-Q bdpt_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

Commission File Number 000-54949

BioAdaptives Inc.

(Exact name of registrant as specified in its charter)

Delaware		46-2592228
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

2620 Regatta Drive, Suite 102, Las Vegas, NV		89128
(Address of principal executive offices)		(Zip Code)

(702) 659-8829

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non- accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-Accelerated filer	☐	Smaller reporting Company	☒
Emerging Growth Company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ YES ☒ NO

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

776,464,023 common shares issued and outstanding as of August 10, 2023

Form 10-Q

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	3

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of operations	15

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	22

Item 4.	Controls and Procedures	22

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	24

Item 1A.	Risk Factors	24

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25

Item 3.	Defaults Upon Senior Securities	25

Item 4.	Mine Safety Disclosure	25

Item 5.	Other Information	25

Item 6.	Exhibits	25

Signatures		26

Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	June 30,			December 31,
	2023			2022

ASSETS
Current Assets:
Cash	$	40,121		$	25,405
Marketable securities		21			42
Inventory		6,487			8,877
Total Current Assets		46,629			34,324

License and patent, net		1,644			2,990
TOTAL ASSETS	$	48,273		$	37,314

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities:
Accounts payable and accrued liabilities		419,685			409,920
Derivative liabilities		930,072			686,856
Current portion of convertible notes - net of discount of $42,512 and $7,647		315,738			381,793
Note payable - related party		61,290			10,246
Total Current Liabilities		1,726,785			1,488,815

Total Liabilities		1,726,785			1,488,815

Stockholders’ Deficit:
Preferred stock, ($0.0001 par value, 10,000,000 shares authorized;
Series A Preferred Stock 4,000,000 shares designated; 1,600,000 issued and outstanding, respectively		160			160
Series B Preferred Stock 6,000,000 shares designated; no share issued and outstanding		-			-
Common stock ($0.0001 par value, 1,250,000,000 shares authorized; 576,474,023 and 252,554,765 shares issued and outstanding, and 10,000 issuable, respectively)		57,647			25,255
Additional paid-in capital		6,246,464			6,074,763
Accumulated deficit		(7,982,783	)		(7,551,679	)
Total Stockholders’ Deficit		(1,678,512	)		(1,451,501	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	48,273		$	37,314

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

	Three Months Ended						Six months ended
	June 30,						June 30,
	2023			2022			2023			2022

Revenues	$	2,339		$	4,322		$	5,715		$	9,855
Cost of revenue		849			2,169			2,245			5,759
Gross Profit		1,490			2,153			3,470			4,096

Operating Expenses
General and administrative		14,516			87,517			26,552			192,717
Professional fees		42,246			34,112			50,496			71,944
Amortization of license and patent		677			23,821			1,346			56,988
Total Operating Expenses		57,439			145,450			78,394			321,649

Other Income (Expense)
Unrealized gain (loss) on marketable securities		(10	)		(106	)		(20	)		(127	)
Interest expense		(52,253	)		(75,367	)		(103,316	)		(105,466	)
Change in fair value of derivative liabilities		(35,705	)		(5,067	)		(252,844	)		(167,822	)
Total Other Expense		(87,968	)		(80,540	)		(356,180	)		(273,415	)

Loss before income taxes		(143,917	)		(223,837	)		(431,104	)		(590,968	)

Net Loss	$	(143,917	)	$	(223,837	)	$	(431,104	)	$	(590,968	)

Net Loss Per Common Share:
Basic and Diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.01	)

Weighted Average Number of Common Shares Outstanding:
Basic and Diluted		441,742,955			67,545,413			355,268,125			60,677,388

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

(UNAUDITED)

For the Three and Six months ended June 30, 2023

					Common				Additional
	Series A Preferred stock				stock				paid-in		Accumulated
	Shares		Amount		Shares		Amount		capital		Deficit			Total

Balance, December 31, 2022		1,600,000	$	160		252,554,765	$	25,255	$	6,074,763	$	(7,551,679	)	$	(1,451,501	)

Common stock issued for conversion of debt		-		-		132,382,517		13,239		94,797		-			108,036
Net loss for the period		-		-		-		-		-		(287,187	)		(287,187	)
Balance, March 31, 2023		1,600,000	$	160		384,937,282	$	38,494	$	6,169,560	$	(7,838,866	)	$	(1,630,652	)

Common stock issued for conversion of debt		-		-		191,536,741		19,153		76,904		-			96,057
Net loss for the period		-		-		-		-		-		(143,917	)		(143,917	)
Balance, June 30, 2023		1,600,000	$	160		576,474,023	$	57,647	$	6,246,464	$	(7,982,783	)	$	(1,678,512	)

For the Three and Six months ended June 30, 2022

									Additional
					Common stock				paid-in		Accumulated
	Shares		Amount		Shares		Amount		capital		Deficit			Total

Balance, December 31, 2021		1,600,000	$	160		50,819,780	$	5,082	$	5,557,828	$	(6,656,109	)	$	(1,093,039	)

Common stock issued for conversion of debt		-		-		7,540,799		754		51,263		-			52,017
Debts forgiveness - related party		-		-		-		-		10,000		-			10,000
Net loss for the period		-		-		-		-		-		(367,131	)		(367,131	)
Balance, March 31, 2022		1,600,000	$	160		58,360,579	$	5,836	$	5,619,091	$	(7,023,240	)	$	(1,398,153	)

Common stock issued for conversion of debt		-		-		19,096,904		1,910		119,705		-			121,615
Warrant issued for acquisition of patent		-		-		-		-		5,429		-			5,429
Net loss for the period		-		-		-		-		-		(223,837	)		(223,837	)
Balance, June 30, 2022		1,600,000	$	160		77,457,483	$	7,746	$	5,744,225	$	(7,247,077	)	$	(1,494,946	)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOW

(UNAUDITED)

	Six months ended
	June 30,
	2023			2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(431,104	)	$	(590,968	)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative liabilities		252,844			162,755
Amortization of license and patent		1,346			56,988
Amortization of debt discount		82,385			79,547
Unrealized (gain) loss on investments in marketable securities		21			127
Changes in operating assets and liabilities:
Inventory		2,390			(5,897	)
Accounts payable and accrued liabilities		15,790			157,431
Due to related party		-			1,803
Net Cash Used in Operating Activities		(76,328	)		(138,214	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceed from related party		51,044			1,623
Repayment to related party		-			(1,623	)
Repayment of notes payable - related party		-			(25,272	)
Proceeds from convertible notes		40,000			125,000
Net Cash Provided by Financing Activities		91,044			99,728

Net change in cash		14,716			(38,486	)
Cash at beginning of period		25,405			82,936
Cash at end of period	$	40,121		$	44,450

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	$	-		$	-
Cash paid for interest	$	-		$	4,728

NON-CASH INVESTING AND FINANCING ACTIVITIES
Derivative liability recognized as debt discount	$	110,000		$	92,000
Issuance of common stock for conversion of debt	$	204,093		$	173,632
Debts forgiveness - related party	$	-		$	10,000
Warrant issued for Patent’s acquisition	$	-		$	5,429

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

BIOADAPTIVES, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business

BioAdaptives, Inc. (“BioAdaptives” or the “Company”) was incorporated in Delaware on April 19, 2013, under the name Apex 8, Inc. Shortly afterwards, the Company’s control person sold his interest; new owners appointed management and changed its name to BioAdaptives, Inc. The Company acquired assets relating to the investigation, development and marketing of nutraceutical products; equipment designed to improve the bioavailability of nutrients in humans and animals; and licenses for specific products.

We commenced investigation of the role of various botanicals in primitive cell development and proliferation, including certain algae along with herbs used in Traditional Chinese Medicine and Ayurvedic Practice. In the course of this investigation, BioAdaptives identified several potential human and animal products. The Company terminated further work on the equipment and products licensed in its early stages to concentrate on these products, for both human and animals.

The Company’s current nutraceutical products are natural plant- and algal-based dietary supplements for humans and animals developed with our knowledge of natural foods. Our product lines include PluriCell®, PluriPain®, and PrimiLung™ for humans along with Equine All-in-One™ and a related Booster for horses.

Our human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. The science behind our products has proven to be effective for performance enhancement and pain relief for horses and dogs as well as providing improvements in appearance and we have developed products to utilize these advances.

The Company also markets the Lung Cleanser™ medical device, which is sold with our PrimiLung® product as part of a Lung Armor™ package. Additionally, during this reporting period, the Company acquired patent rights to a method to embed oxygen in water and is developing commercial products based on this technology that will augment and complement our current product lines.

All of these products are sold under licensing and manufacturing agreements with third parties and our current activities are reliant on marketing and distributing products developed and owned by others.

In February 2022, the Company acquired US Patent rights to a process that increases dissolved oxygen in water. The process produces MorO2, ingestion of which is believed to increase diffusion of oxygen into muscle tissues. The Company is developing a business plan to manufacture and market products based on the MorO2 technology.

The Company’s corporate office is located at 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128.

2. SUMMARY OF SIGNIFICANT POLICIES

Basis of Presentation

The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10K. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim period presented, have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10K filed with SEC on June 30, 2023, have been omitted.

Table of Contents

Use of estimates

The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Earnings (loss) per share

Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued.

Financial Instruments and Fair Value Measurements

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

The following table summarizes fair value measurements by level as of June 30, 2023, and December 31, 2022, measured at fair value on a recurring basis:

	Total Carrying Value		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	as of June 30, 2023		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities	$	21	$	21	$	-	$	-

Liabilities
Derivative liabilities	$	930,072	$	-	$	-	$	930,072

	Fair Value Measurements as of December 31, 2022, Using:
	Total Carrying Value as of December 31,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2022		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities, 105,736 shares of common stock of Hemp, Inc. (HEMP)	$	42	$	42	$	-	$	-

Liabilities
Derivative liabilities	$	686,856	$	-	$	-	$	686,856

Table of Contents

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used a Black Scholes valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

3. GOING CONCERN

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $7,982,783 as of June 30, 2023. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. Obtaining additional financing, successful development of the Company’s contemplated plan of operations, and the transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities aa of June 30, 2023 and December 31, 2022, consists of the following:

	June 30,		December 31,
	2023		2022
Accounts payable	$	1,394	$	6,939
Accrued salary		300,000		300,000
Accrued interest		116,872		101,966
Accrued liabilities		1,419		1,015
	$	419,685	$	409,920

Table of Contents

5. CONVERTIBLE NOTES

Convertible notes as of June 30, 2023 and December 31, 2022, consist of the following:

	June 30,			December 31,
	2023			2022
Convertible Notes - originated in April 2018	$	95,000		$	95,000
Convertible Notes - originated in June 2018		166,000			166,000
Convertible Notes - originated in October 2018		50,000			50,000
Convertible Notes - issued fiscal year 2022		-			78,440
Convertible Notes - issued fiscal year 2023		47,250			-
Total convertible notes payable		358,250			389,440

Less: Unamortized debt discount		(42,512	)		(7,647	)
Total convertible notes		315,738			381,793

Less: current portion of convertible notes		315,738			381,793
Long-term convertible notes	$	-		$	-

For the six months ended June 30, 2023 and 2022, the interest expense on convertible notes was $20,763 and $25,556, respectively. As of June 30, 2023 and December 31, 2022, the accrued interest was $115,656 and $100,919, respectively.

The Company recognized amortization expense related to the debt discount of $82,385 and $79,547 for the six months ended June 30, 2023 and 2022, respectively, which is included in interest expense in the statements of operation.

Conversion

During the six months ended June 30, 2023, the Company converted notes with principal amounts of $78,440 and accrued interest of $6,026 into 323,919,258 shares of common stock. The corresponding derivative liability at the date of conversion of $64,258 was credited to additional paid in capital.

Convertible Notes – Issued during the year ended December 31, 2018

During the year ended December 31, 2018, the Company issued a total principal amount of $426,000 in convertible notes for cash proceeds of $426,000. The convertible notes were also provided with a total of 107,000 common shares valued at $22,210. The terms of these convertible notes are summarized as follows:

	·	Term two years;

	·	Annual interest rates 12%;

	·	Convertible at the option of the holders at any time

	·	Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price.

Convertible Notes - Issued during the year ended December 31, 2021

During the year ended December 31, 2021, the Company issued a total principal amount of $222,500 in convertible note for cash proceeds of $205,000. The terms of convertible note are summarized as follows:

	·	Term one year;

	·	Annual interest rates 10%;

	·	Convertible at 180 days from issuance

	·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

Table of Contents

During the year ended December 31, 2021, the Company converted principal of $172,050 and accrued interest of $6,200 into 17,787,355 shares of common stock.

Convertible Notes - Issued during the year ended December 31, 2022

During the year ended December 31, 2022, the Company issued a total principal amount of $211,500 in convertible notes for cash proceeds of $195,000. The terms of convertible notes are summarized as follows:

	·	Term one year;

	·	Annual interest rates 10%;

	·	Convertible at 180 days from issuance

	·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

Convertible Notes - Issued during the year ended December 31, 2023

During the six months ended June 30, 2023, the Company issued a total principal amount of $47,250 in convertible notes for cash proceeds of $40,000. The terms of convertible notes are summarized as follows:

	·	Term one year;

	·	Annual interest rates 10%;

	·	Convertible at any time

	·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

The Company valued the conversion feature using the Black-Scholes pricing model. The fair value of the derivative liability for all the notes that became convertible, including the notes issued in prior years, during the six months ended June 30, 2023, amounted to $569,854, and $117,250 of the value assigned to the derivative liability was recognized as a debt discount to the notes while the balance of $459,854 was recognized as a “day 1” derivative loss.

6. DERIVATIVE LIABILITIES

The Company analyzed the conversion option for derivative accounting consideration under ASC 815, Derivatives and Hedging, and hedging, and determined that the instrument should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The Company accounts for warrants as a derivative liability due to there being no explicit limit to the number of shares to be delivered upon settlement of all conversion options.

Fair Value Assumptions Used in Accounting for Derivative Liabilities.

ASC 815 requires we assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item.

Table of Contents

The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of June 30, 2023. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note is estimated using the Black-Scholes valuation model.

For the six months ended June 30, 2023, and the year ended December 31, 2022, the estimated fair values of the liabilities measured on a recurring basis are as follows:

	Six months ended		Year ended
	June 30,		December 31,
	2023		2021
Expected term	0.18- 1.00 years		0.06 - 0.51 years
Expected average volatility	141% - 240%		72% - 164%
Expected dividend yield		-		-
Risk-free interest rate	4.76% - 5.50%		0.17% - 4.72%

The following table summarizes the changes in the derivative liabilities during the six months ended June 30, 2023.

Fair Value Measurements Using Significant Observable Inputs (Level 3)

Balance - December 31, 2022	$	686,856

Addition of new derivatives recognized as debt discounts		110,000
Addition of new derivatives recognized as loss on derivatives		459,854
Settled on issuance of common stock		(119,628	)
(Gain) loss on change in fair value of the derivative		(207,010	)
Balance - June 30, 2023	$	930,072

The aggregate (gain) loss on derivatives during the six months ended June 30, 2023, and 2022 was as follows.

	Six months ended
	June 30,
	2023			2022
Day one loss due to derivative liabilities on convertible notes	$	459,854		$	28,960
(Gain) loss on change in fair value of the derivative liabilities		(207,010	)		138,862
	$	252,844		$	167,822

7. STOCKHOLDERS’ EQUITY

Preferred Stock

On January 24, 2022, the Board of Directors of the Company’s, approved for an increase in the number of authorized shares of the Company’s preferred stock from 5,000,000 shares to 10,000,000 shares.

The Company is authorized to issue 10,000,000 shares of $0.001 par value preferred stock, of which 4,000,000 have been designated as Series A Preferred Stock and 6,000,000 have been designated as Series B Preferred Stock.

Series A Preferred Stock

On February 6, 2020, the Company established its Series A Preferred Stock, par value $0.001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 4,000,000 shares of Series A Preferred Stock.

Table of Contents

The Company may use the Series A Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series A Preferred Stock have enhanced voting privileges under certain circumstances; the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 5:1 ratio.

There are 1,600,000 shares of Series A shares issued as of the date of this filing.

Series B Preferred Stock

On January 24, 2022, the Company established its Series B Preferred Stock, par value $0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 6,000,000 shares of Series B Preferred Stock.

The Company may use the Series B Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series B Preferred Stock have enhanced voting privileges (100:1); the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 10:1 ratio.

As of the date of this filing, no shares of Series B Preferred Stock are issued and outstanding.

Common Stock

On March 7, 2023, the Company amended its articles of incorporation to increase its authorized common shares from 750,000,000 to 1,250,000,000; this increase will be effective March 27, 2023.

As of June 30, 2023 and December 31, 2022, there were 576,474,023 and 252,544,765 shares of the Company’s common stock issued and outstanding, respectively. In addition, as of June 30, 2023, and December 31, 2022, there were 10,000 shares of the Company’s common stock issuable.

Fiscal year 2023

During the six months ended June 30, 2023, the Company issued 323,919,258 shares of common stock valued at $204,093 for conversion of debt.

Warrant

On February 6, 2022, in conjunction with purchase of patent, the Company granted 1,000,000 shares for period of two years with exercise price of $0.006 per share. The fair value of granted shares at the issuance date was $5,429. The Company recorded warrant as additional paid-in-capital.

The estimated fair values of the warrant are as follows:

	Year Ended
	December 31,
	2022
Expected term	2.00 years
Expected average volatility		235	%
Expected dividend yield		-
Risk-free interest rate		1.31	%

Table of Contents

8. RELATED PARTY TRANSACTIONS

Notes payable – related party

During the six months ended June 30, 2023 and 2022, the Company repaid notes payable to a related party and accrued interest of $0 and $30,000 and recognized interest of $168 and $363, respectively.

As of June 30, 2023 and December 31, 2022, the Company recorded notes payable - related party of $8,444 and $8,444 and accrued interest of $1,214 and $1,047, respectively. The note is a 4% interest bearing promissory note that the term is 1 year.

Due to related party

During the six months ended June 30, 2023, Dr. Edward E. Jacobs, M.D., our CEO, advanced $51,044 for operating expenses. As of June 30, 2023 and December 31, 2022, the Company recorded due to related party of $52,846 and $1,802, respectively.

9. SUBSEQUENT EVENTS

During July and early August, The REG A filed and as amended in November 2022 for 200,000,000 common shares at $0.001 were fully subscribed. This provides the Company with the liquidity to pursue further research into its lead products: Pluripain^®, SleepEZ™ and Primilungs™ and move the Company’s testing, development and marketing programs forward. The Company is also in discussion with marketing specialists in expanding its footprint on the Amazon market place now that the RegA has been fully subscribed and provide the necessary funding for more intensive marketing efforts. Since the appointment of FCBTherapy as its exclusive Distributor, LiveStock impact is withdrawing from its own websale and is encouraged with the first initial wholesale order from FCBTherapy is over $9000 which is double the last 6 months gross sales.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD LOOKING STATEMENTS

This current report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

Our financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock.

As used in this quarterly report, the terms “we”, “us”, “our”, “Company” and “BioAdaptives” mean BioAdaptives Inc., unless otherwise indicated.

Table of Contents

1. OUR BUSINESS

Overview

BioAdaptives’ core business is to investigate, market and distribute natural plant, algal and mushroom-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties.

Effective November 15, 2021, the Company entered into a marketing agreement for an FDA-cleared medical device, the Lung Flute™, which the Company called Lung Cleanser™. The Company is also exploring agreements with other medical device manufacturers; the owners of intellectual property relating to medical devices and processes; and marketing companies associated with these manufacturers and owners.

The Company’s current products include dietary supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients in foods and beverages. Human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. The science behind our human products has proven to be effective for performance enhancement and pain relief for horses and dogs as well as providing improvements in appearance.

Our current product line for humans includes PluriPain®, PrimiLungs™, SleepEZ™, MindnMemory™ and Cell Rejuven™. Cell Rejuven™ the most recently launched product is an anti-aging cell rejuvenation formulation. We also market the Lung Cleanser™ and PrimiLungs™ product in our Lung Armor™ packaging, emphasizing the anti-viral properties of the nutraceutical and general respiratory health benefits from use of the non-invasive FDA-cleared device. MindNMemory™ is a nootropic formulation designed to enhance mental clarity and memory; SleepEZ™ is a natural soporific that aids relaxation and sleep quality. We acquired the SleepEZ™ license in 2021 as PrimiSleep™, and the revised formulation for MindnMemory™ during 2022, and have commenced marketing activities for these products. Sales of the Lung Cleanser™ have not met our expectations and we anticipate concentrating in marketing this device through wholesale channels instead.

Our animal products include an Equine All-in-One™ and Equine All-In-One Plus™ formulation, which we market to trainers, horse owners and boarding stables, and a Canine All-in-One™ that we market directly to consumers. Anecdotal and testimonial reports are that the equine products provide significant relief from exercise induced pulmonary hemorrhaging, as well as improved coat and mane appearance and hoof health. The canine products have demonstrated significant rejuvenating benefits for older dogs, improving overall appearance and energy levels. Effective April 2023, FBRTherapy Division has been appointed its exclusive Distributor for all LiveStock Impact’s products, as such The Company also negotiated with the supplier for the exclusive marketing rights to these products from the non-exclusive license it has held since June 2022.

Effective February 2, 2022, the Company acquired the option to purchase U.S. Patent No. 9,783,432B (the “Patent”), covering technology used in enhancing the capability of water to hold significantly larger amounts of oxygen. Since June 6, 2022, we entered into a services agreement with Wildpack Beverages in Las Vegas, Nevada to co-pack a pilot run (1333 cases) of this Product. However, since technical problems prevented completion of the planned pilot run, we are still working to rectify these issues and explore how to deploy the technology.

Table of Contents

Since the latter part of March, the Company has started to explore the Botanical Drugs sphere. We acquires the non exclusive licenses from Dr. Yaguang Liu, LY Research for Glucose Management, Eye Health due to Myopia and Presbyopia and a resveratrol product. Dr Liu has had over 40 years of research and development in the Botanical Drugs area. We are exploring the opportunities in deploying these patented products for nutraceutical use for human and animal initially.

While we continue to investigate and acquire nutraceutical products for humans and animals, all of our current activities are reliant on marketing and distributing products developed and owned by others. Currently, other than the two equine formulations where we have the exclusive marketing rights, we do not own the formulations for our key products and manufacture and market them under an agreement with the developer that requires payment of a royalty and a license agreement. We are negotiating towards the acquisition of some of these formulations.

We are reliant on direct web sales of the nutraceutical lines for humans and the All-in-One animal products for revenues, none of which has produced any significant revenue yet. Because of this, we are now exploring the wholesale and affiliate markets for their sales. We have very limited experience in marketing and have yet to develop reliable sales expectations and forecasting.

Market and Marketing

We market our science-based, quality nutraceuticals to a broad base of the population in the U.S., and are exploring marketing prospects in Asia, Australasia, the Middle East, and Europe. The Company’s current target markets also include equine and canine companion animals and equine competitors in the U.S., Australasia and the Middle East.

During June 2021, we commenced use of social media professionals and existing connections to create awareness about our human products’ benefits. The initial results were not satisfactory and a recast, animal product-specific program that followed later in 2021, did not achieve the desired results. We are developing affiliate marketing opportunities and recognize that a broader campaign using traditional advertising along with social media and more contemporary marketing tools is necessary. We started to re-launch our internet-based marketing activities in Q1 2023, extending the individual product websites, revamping the Company’s website, continuing to explore wholesale, white-label opportunities and placing products on Amazon. To expand its footprint on the Amazon sales channel, we are discussing with amazon marketing specialist in third party management of our products on Amazon.

We are pursuing scientific surveys and other testing to demonstrate the usefulness of our products. While we do not anticipate developing testing protocols suitable for FDA approvals, we expect anecdotal and testimonial reports that will be useful in our marketing efforts. The Company participated in a survey involving the use of PluriPain® by patients suffering from Gadolinium Deposition Disease (“GDD”), and a combination of products for COVID Long Hauler patients. In the GDD survey, 60% of a small subject sample reported significant relief. The COVID Long Hauler survey has limited participation to date and no reported results. We continue to support these efforts.

Although we believe our newly formulated MindNMemory™ and Cell Rejuven™ products are substantial improvement over PrimiLive®, our other products have not substantially changed: We offer premium nutraceutical preparations containing the best quality all-natural botanical, algal and mushroom ingredients. We will continue to emphasize the unique qualities, use and function of our nutraceuticals. We intend to create market share in our target demographic by (i) emphasizing the benefits of our proprietary algal-mushroom based, all-natural, stimulant-free, sugar-free, non-GMO ingredients that combine with proven Traditional Chinese Medicine and Ayurvedic botanicals into science-based formulations, (ii) investigating additional products in response to market demand and testing, and (iii) utilizing our marketing operation to act as its sales and distribution arm to seek additional channels for sales coverage.

As noted above, we entered into licensing agreements for the PrimiLive® and PrimiSleep™ products during 2021 and changed the name PrimiSleep™ to SleepEZ™ to reflect on its capabilities as well as developing our reformulated MindnMemory™ during 2022. We also launched the advanced Cell product, Cell Rejuven™. While these products are all-natural botanical formulations, as our other nutraceutical products, they represent a departure from our existing product lines because they are targeted to specific markets: MindnMemory™ is a nootropic, intended to improve concentration and mental acuity; our initial marketing efforts are oriented toward Seniors and e-gamers. SleepEZ™ is intended for use as an aid to relaxation, with an emphasis on improving the quality of sleep. Cell Rejuven™ is an improved primitive cell anti-aging formulation that promotes high quality hair and nail growth, as well as improving mood We believe these products can be used in a complementary manner, to maintain on-task endurance and then to unwind and recover from such activities.

Table of Contents

We are furthering the use of a formulation of PluriPain® targeted toward the symptoms of pre-menstrual syndrome and menstrual pain. Anecdotal and testimonial reports have long noted that users obtain relief from these symptoms with use of the PluriPain® product, and we have made adjustments and additions to the formulation to target these symptoms. Early reports are promising, and we expect marketing efforts to emphasize the usefulness of our product to alleviate PMS-related symptoms. By popular requests, the Company is also working with developers on a menopause supplement.

We are also exploring the combination of PluriPain®, PrimiLung™ and SleepEZ™ for those still suffering COVID effects in the on-going Survey conducted by Regina Sutton, M.D. These specific formulations address some of the most troubling symptoms of long-term COVID sufferers, including brain fog, pain and sleep problems.

In light of the availability of marketing funding with the Reg A completion, we will be looking for collaboration with others to promote our products, and to also conduct surveys with larger groups of participants to further confirm their efficacy, which anecdotal reports have in the past confirmed.

With regard to animal products, the Company’s Livestock Impact Division under the direction its President, Bruce Colclasure, a National Cutting Horse Association champion, who owns and operates the Flying C Bar Ranch in Oklahoma and a breeder and trainer of over 80 NCHA champion cutting horses, continues to explore new opportunities in this emerging market. Mr. Colclasure uses and endorses our Equine All-in-One™ and derivative booster products providing valuable feedback and testimonials regarding their benefits. In addition, a high-performance special formulation of our All-in-One product continues to be marketed with exceptional results. We expect to expand the outreach in 2023.

In light of the failures of our past social media campaigns, we recommenced a social media effort this quarter with better response. The Company continues its marketing affiliate outreach program for the equine products, directly contacting the principals of horse clubs and associations, offering discounts, samples and other inducements, seeking to develop “product champion” and “maven” relationships. We contacted principals in organizations with thousands of members and many more thousands of horses. Since the 4th Quarter 2022, we have been distributing samples and marketing materials to over 40 principals and influencers in regional and breed-specific equine associations and in anticipation of receiving feedback from these marketing initiatives in 2023.

Manufacturing

All of the Company’s nutraceutical products are considered dietary supplements or natural foods, and we carefully avoid making health, drug or disease cure claims that could trigger regulatory compliance issues and affect our ability to market BioAdaptives products. Our active ingredients are all plant-, algal and mushroom-based and sourced worldwide from reputable suppliers who employ stringent compliance and sustainable agriculture practices .

We contract with manufacturers to assemble and package our products, all of which are subject to our inspection and approval. Fulfillment of retail internet and direct-to-reseller orders are conducted from our own facilities. BioAdaptives actively investigates new products, techniques and novel applications of existing products or technology in our research. The Company’s research work has centered on investigations of all-natural supplement formulations that activate primitive cells, including stem cells and their derivatives, and natural ingredients that encourage stem cell proliferation.

Table of Contents

As noted above, it is our intention to operate primarily as a research and marketing company, developing consumer markets for nutraceutical products and medical devices that we license or market for others.

Employees

The Company currently has 3 executive employees and 3 part-time employees. We retain hourly labor on an as-needed basis and professional consultants to operate our business. The management of the Company expects to continue to use outside consultants, attorneys, and accountants, as necessary, as long as it is seeking and evaluating business opportunities. The need for additional employees, and their availability, will be addressed in connection with the decision whether or not to acquire or participate in specific business opportunities.

2. LIQUITITY AND CAPITAL RESOURCES:

Liquidity -- Financial Performance – Three Months Ended June 30, 2023, and 2022

We had a net loss of $143,917 for the six-month period ended June 30 2023, which was $$79,920less than the net loss of $223,827 for the six-month period ended June 30, 2022. The change in our results is mainly due to the Change in operating expenses.

The following table summarizes key items of comparison and their related increase (decrease) for the three-month periods ended June 30, 2023, and 2022:

	2023			2022			Changes
Revenue		2,339			4,322			(1,987	)
Cost of Sales		849			2,169			1,320
Operation Expenses		57,439			145,450			88,011
Other income (expenses)		(87,968	)		(80,540	)		(7,428	)
Net Income (loss)		(143,917	)		(233,837	)		79,920

Revenue

Our revenues have been derived entirely from product sales.

Cost of Sales

Our cost of sales is primarily derived from contract manufacturing expenses and shipping and handling expenses related to customer fulfillment. We also expense marketing expenses, which includes the cost of samples or products provided for promotional purposes and website content development. We have contracted for consulting services relating to website and product label redesign and another web sales outreach campaign, and we expect expenses to accrue for such services in 3Q 2023, and beyond.

Table of Contents

Operation Expenses

Our general, administrative and professional fees are largely attributable to office, rent, advertising, consultants and transfer agent, legal, accounting and audit fees related to our reporting requirements as a public company as well as stock-based compensation for officers, directors and consultants.

Other Income (Expense)

The Company recorded interest expenses of $52,253 and $ 75,367 for the six months ended June30, 2023, and 2022.

Net Loss

As a result of our operating expenses the Company reported a net loss of $ 143,917 and $ 223,837 for the six months ended June 30, 2023, and 2022.

Capital Resources – Balance Sheet and Cash Flows

Our balance sheet as of June 30 2023, reflects current assets of $46,629 , including cash in the amount of $40,121 . We currently meet cash requirements by infusions of cash from issuance of notes to finance partners, through RegA subscriptions and advances from shareholders. Most of these notes have conversion features that require accounting for derivative liabilities. We are hopeful that our Reg. A+ offering will help to reduce our financing costs but can provide no assurances as to whether our offering will be successful.

Working Capital (Deficiency)

	June 30, 2023,			June 30, 2022,			Change
Current Assets		46,629			34,324			12,305
Current Liabilities		1,726,785			1,488,815			(225,661	)
Working Capital (Deficiency)		(1,680,165	)		(1,454,491	)		(225,661	)

Cash Flows

	Six Months Ended
	June 30
	2023			2022			Change
Cash provided by (used in) Operating Activities		(76,328	)		(138,214	)		61,886
Cash provided by (used in) Financing Activities		91,044			99,728			(8,684	)
Net Increase (Decrease) In Cash During Period		14,716			(38,486	)		53,202

Table of Contents

Net cash used by operating activities during the six months ended June 30, 2023, was $ 76,328 a decrease of $ 61,886 from net cash used of $138,214 in operating activities during the six months ended June 30, 2022.

Cash Flows from Financing Activities

Net cash provided by financing activities during the three months ended June 30, 2023, was $ 91,044 , a decrease of $ 8,684 from net cash provided in financing activities during the six months ended June 30, 2022.

As of June 30, 2023, we have insufficient cash to operate our business at the current level for the next twelve months and insufficient cash to achieve our business goals. The success of our business plan beyond the next 12 months is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

Critical Accounting Estimates -- Going Concern

We are required to provide qualitative and quantitative information necessary to understand any critical accounting estimations, including uncertainties associated with such estimates. Our critical accounting estimates, as well as the financial statements contained in this report, are all reliant on the assumption that we will continue as a going concern, which contemplates our ability to generate sufficient cash flows from operations and financing activities necessary to continue in business by employing our assets and satisfying our liabilities in the normal course of business.

On June 30, 2023, we had $40,121 of cash on-hand and an accumulated deficit of $7,982,783 , and as noted throughout this report and our financial statements and notes thereto, our independent auditors expressed their substantial doubt as to our ability to continue as a going concern as of December 31, 2022. We anticipate incurring significant losses in the future. We do not have an established source of revenue sufficient to cover our operating costs. Our ability to continue as a going concern is dependent upon our ability to successfully compete, operate profitably and/or raise additional capital through other means. If we are unable to reverse our losses, we will have to discontinue operations.

Because our business plan relies on marketing products we license from others, our capital requirements are generally limited to general operations and administration, including the costs of continuing as a public company, and our variable costs scale up or down based on our actual sales. We believe that increasing our marketing expenses will be critical to establishing sales sufficient to cover our expenses and, if possible, generate a profit. We anticipate using our existing financing operations to do so, which will almost certainly require either the issuance of equity or increases in existing levels of debt or, most likely, both.

Management’s plans include the raising of capital through the equity markets to fund future operations, seeking additional acquisitions, and generating revenue through our business. However, even if we do raise sufficient capital to support our operating expenses and generate adequate revenues, there can be no assurances that the revenue will be sufficient to enable us to develop business to a level where we will generate profits and positive cash flows from operations. These matters raise substantial doubt about our ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

Table of Contents

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, and capital expenditures or capital resources that are material to stockholders.

Critical Accounting Policies

Our financial statements are based on the application of accounting principles generally accepted in the United States (“US GAAP”). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenue, and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to US GAAP and are consistently and conservatively applied that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

Recent Accounting Pronouncements

The Company has evaluated recent pronouncements through Accounting Standards Updates (“ASU”) and believes that none of them will have a material impact on the Company’s financial position, results of operations or cash flows.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company,” we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report, June 30, 2023. This evaluation was carried out under supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Based upon that evaluation, including our Chief Executive Officer and Chief Financial Officer, we have concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report due to a material weakness in our internal control over financial reporting, which is described below

Table of Contents

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of June 30, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of June 30, 2023, our internal control over financial reporting was not effective. Our management identified the following material weaknesses in our internal control over financial reporting, which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment. and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

We plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we hope to implement the following changes during our fiscal year ending December 31, 2023: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out in (i) and (ii) are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

To a certain extent, the size of our operation provides inherent checks and balances relative to internal controls: Because of our limited staff size and the integration of our executives and directors in operations, the prospect for significant internal control failures resulting in unreliable financial statements or worse is remote. Regardless, we recognize the importance of multiple layers of reporting and controls and are working toward improving our capabilities.

Changes in Internal Control over Financial Reporting

There was no change in the Company’s internal control over financial reporting that occurred during the Company’s most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

At this time, we know of no pending legal proceedings to which we are a party, either individually or in the aggregate. We are from time-to-time, during the normal course of our business operations, subject to various litigation claims and legal disputes. There are no such claims or disputes pending at this time and we have not been notified of any possible claims or disputes.

Item 1A. Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Covid-19 Pandemic Impact and Risk

At this time, it is not possible to fully assess the impact of the COVID-19 pandemic on the Company’s operations and capital requirements. While we have noted that economic headwinds have eased generally, our business is impacted by numerous other influences. Business activities from 1Q 2020 onward were substantially curtailed: Our key executives were unable to travel, which impacted on our financing operations. Consumer demand was generally down in our target markets, even though we offer products that are generally considered to promote health. We delayed much of our marketing activity due to travel, funding and perceived demand issues.

We re-launched our marketing efforts during 1Q 2022, but these have slowed to gain traction. The other factors impeding the growth of our business have significantly changed: travel restrictions have eased, and our finance partners have cash for investments or debt issuance. Consumer demand for our products, however, has not increased significantly. We believe this has more to do with poor reception to our marketing initiatives and the fact that we operate in a crowded market space, with several better-known and capitalized competitors.

The CDC reports that US children and adults should remain vigilant to new mutations of the COVID-19 virus, and that the pandemic will likely continue to impact groups that comprise our intended consumers. Should the pandemic reignite, the Company may be faced with the same headwinds we saw during 2021, which may adversely affect the Company’s ability to (i) retain employees and consultants; (ii) obtain additional financing on terms acceptable to the Company, if at all; (iii) delay regulatory submissions and approvals, if required; (iv) delay, limit or preclude the Company from securing manufacturing sites, partnerships or marketing agreements; (v) delay, limit or preclude the Company from achieving technology or product development goals, milestones, or objectives; and (vi) preclude or delay entry into joint venture or partnership arrangements. The occurrence of any one or more of such events may affect the Company’s ability to execute its business plan.

During 2Q 2022, the Company commenced sponsorship of a COVID Long Hauler Survey, providing funding for scientific uses and samples of our pain, pulmonary and sleep products to participants. While we do not (and cannot) make any manner of drug-type or treatment claims regarding disease, the Company has received anecdotal reports that certain combinations of our products provide relief from certain long-term COVID symptoms, including brain fog, persistent pain, and sleep disruptions. Although we are careful not to make any COVID-related claims in our marketing materials, we intend to pursue this survey for general scientific purposes to determine additional uses for our products.

The Company’s priority and commitment is to the health and security of its team members, their families and its partners through this unprecedented pandemic.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

We issued equity securities during this reporting period to satisfy convertible notes to our finance partner, 1-800 Diagonal Lending, LLC.; the structure and terms of these obligations is the same as made in previous periods. The table below sets out these issuances during the period from April 1 2023 to and including June 30 2023

1800 DIAGONAL LENDING, LLC	19,032,298	05/26/2023
1800 DIAGONAL LENDING, LLC	19,032,298	05/31/2023
1800 DIAGONAL LENDING, LLC	21,041,667	06/01/2023
1800 DIAGONAL LENDING, LLC	21,055,556	06/02/2023
1800 DIAGONAL LENDING, LLC	21,055,556	06/05/2023
1800 DIAGONAL LENDING, LLC	21,055,556	06/06/2023
1800 DIAGONAL LENDING, LLC	21,055,556	06/07/2023
1800 DIAGONAL LENDING, LLC	21,055,556	06/07/2023
1800 DIAGONAL LENDING, LLC	27,152,778	06/08/2023
Total	191,536,741

An additional note will come due during end December 2023. We anticipate issuance of common shares upon 1800 Diagonal Lending’s demand.

Item 3. Defaults Upon Senior Securities

The Company has no senior securities, but has outstanding instruments previously characterized as unsecured convertible debentures. These instruments are not senior to any other Company obligation. The Company arranged extension and forbearance agreements with the holders of the 12% Debentures, which were issued in 2018 and were due at various times in 2020. Our agreement called for the extension of these obligations on the same terms until December 31, 2021, in exchange for current interest payments and delivery of 280,000 shares of its common stock (total). We are currently in default on these obligations but are working on an alternative resolution.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Nothing to add.

Item 6. Exhibits

31.1	Section 302 Certification by the Principal Executive Officer

31.2	Section 302 Certification by the Principal Financial Officer

32.1	Section 906 Certification by the Principal Executive Officer

32.2	Section 906 Certification by the Principal Financial Officer

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		BioAdaptives Inc. (Registrant)

Dated: August 11, 2023		/s/ Dr. Edward E. Jacobs, M.D.
		Dr. Edward E. Jacobs, M.D.
		Chief Executive Officer

		/s/ Robert W. Ellis
		Robert W. Ellis
		Principal Financial Officer

EX-31.1 2 bdpt_ex311.htm CERTIFICATION bdpt_ex311.htm

EXHIBIT 31.1

BIOADAPTIVES INC.

OFFICER’S CERTIFICATE PURSUANT TO SECTION 302

I, Edward E. Jacobs, Jr, certify that:

1.	I have reviewed this Form 10-Q of BioAdaptives Inc.

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared.

	b.	Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, which involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 11, 2023		/s/Edward E. Jacobs, Jr
		By: Edward E. Jacobs, Jr
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 bdpt_ex312.htm CERTIFICATION bdpt_ex312.htm

EXHIBIT 31.2

BIOADAPTIVES INC.

OFFICER’S CERTIFICATE PURSUANT TO SECTION 302

I, Robert W. Ellis, certify that:

1.	I have reviewed this Form 10-Q of BioAdaptives Inc.

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared.

	b.	Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, which involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 11, 2023		/s/Robert W. Ellis
		By: Robert W. Ellis
		Principal Financial Officer

EX-32.1 4 bdpt_ex321.htm CERTIFICATION bdpt_ex321.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioAdaptives Inc. (the Registrant) on Form 10-Q for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Edward E. Jacobs, Jr, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to Edward E. Jacobs, Jr and will be retained by BioAdaptives Inc. and furnished to the Securities and Exchange Commission for or its staff upon request.

Dated: August 11, 2023
/s/ Edward E. Jacobs, Jr

Edward E. Jacobs, Jr

Chief Executive Officer

(Principal Executive Officer)

EX-32.2 5 bdpt_ex322.htm CERTIFICATION bdpt_ex322.htm

EXHIBIT 32.2

BIOADAPTIVES INC.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioAdaptives Inc. (the Registrant) on Form 10-Q for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Robert W. Ellis, Principal Accounting Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

A signed original of this written statement required by Section 906 has been provided to Robert W. Ellis and will be retained by BioAdaptives Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: August 11, 2023
/s/ Robert W. Ellis

Robert W. Ellis

Principal Accounting Officer

EX-101.SCH 6 bdpt-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - CONVERTIBLE NOTES link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - CONVERTIBLE NOTES (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - DERIVATIVE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - STOCKHOLDERS EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - CONVERTIBLE NOTES (Details) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - CONVERTIBLE NOTES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - DERIVATIVE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - DERIVATIVE LIABILITIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - DERIVATIVE LIABILITIES (Details 2) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - SUBSEQUENT EVENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 bdpt-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Entity Interactive Data Current CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Class of Stock [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Current Assets: Cash Marketable securities Inventory Total Current Assets [Assets, Current] License and patent, net TOTAL ASSETS [Assets] LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: Accounts payable and accrued liabilities Derivative liabilities Current portion of convertible notes - net of discount of $42,512 and $7,647 Note payable - related party Total Current Liabilities [Liabilities, Current] Total Liabilities [Liabilities] Stockholders' Deficit: Preferred stock, ($.0001 par value, 10,000,000 shares authorized; Common stock ($.0001 par value, 1,250,000,000 shares authorized; 576,474,023 and 252,554,765 shares issued and outstanding, and 10,000 issuable, respectively) Additional paid-in capital Accumulated deficit Total Stockholders' Deficit [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT [Liabilities and Equity] Convertible notes payable current, discount Preferred stock, shares par value Preferred stock, shares authorized Common stock, shares par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Common stock, shares issuable Preferred stock, shares issued Preferred stock, shares outstanding CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Revenues Cost of revenue Gross Profit [Gross Profit] Operating Expenses General and administrative Professional fees Amortization of license and patent Total Operating Expenses [Operating Expenses] Other Income (Expense) Unrealized gain (loss) on marketable securities Interest expense [Interest Expense] Change in fair value of derivative liabilities Total Other Expense [Other Nonoperating Income (Expense)] Loss before income taxes [Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest] Net Loss [Net Income (Loss) Attributable to Parent] Net Loss Per Common Share: Basic and Diluted Weighted Average Number of Common Shares Outstanding: Basic and Diluted [Weighted Average Number of Shares Issued, Basic] CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT Equity Components [Axis] Series A Preferred Stocks Common Stock Additional Paid-In Capital Accumulated Deficit Balance, shares [Shares, Issued] Balance, amount Common stock issued for conversion of debt, shares Common stock issued for conversion of debt, amount Debts forgiveness - related party Net loss for the period Warrant issued for acquisition of patent Balance, shares Balance, amount CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED) CASH FLOWS FROM OPERATING ACTIVITIES Net loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Adjustments to reconcile net loss to net cash used in operating activities: Change in fair value of derivative liabilities [Fair Value Adjustment of Warrants] Amortization of license and patent Amortization of debt discount Unrealized (gain) loss on investments in marketable securities [Unrealized (gain) loss on investments in marketable securities] Changes in operating assets and liabilities: Inventory [Increase (Decrease) in Inventories] Accounts payable and accrued liabilities [Increase (Decrease) in Accounts Payable and Accrued Liabilities] Due to related party Net Cash Used in Operating Activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM FINANCING ACTIVITIES Proceed from related party Repayment to related party [Repayments of Related Party Debt] Repayment of notes payable - related party [Repayments of Notes Payable] Proceeds from convertible notes Net Cash Provided by Financing Activities [Net Cash Provided by (Used in) Financing Activities] Net change in cash [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect] Cash at beginning of period Cash at end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for income taxes Cash paid for interest NON-CASH INVESTING AND FINANCING ACTIVITIES Derivative liability recognized as debt discount Issuance of common stock for conversion of debt Debts forgiveness - related party Warrant issued for Patent's acquisition DESCRIPTION OF BUSINESS AND HISTORY 1. DESCRIPTION OF BUSINESS AND HISTORY SUMMARY OF SIGNIFICANT POLICIES 2. SUMMARY OF SIGNIFICANT POLICIES GOING CONCERN 3. GOING CONCERN ACCOUNTS PAYABLE AND ACCRUED LIABILITIES 4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES CONVERTIBLE NOTES 5. CONVERTIBLE NOTES DERIVATIVE LIABILITIES 6. DERIVATIVE LIABILITIES STOCKHOLDERS EQUITY 7. STOCKHOLDERS' EQUITY RELATED PARTY TRANSACTIONS 8. RELATED PARTY TRANSACTIONS SUBSEQUENT EVENTS 9. SUBSEQUENT EVENTS Basis of presentation Use of estimates Earnings (loss) per share Financial Instruments and Fair Value Measurements Derivative Financial Instruments Schedule of Fair Value of Measurements of Assets on Recurring Basis Schedule of Accounts Payable and Accrued Liabilities Schedule of Convertible Notes Schedule of Estimated Fair Values of Liabilities Measured on Recurring Basis Summary of Changes in Derivative Liabilities Schedule of (gain) loss on Derivatives Schedule of Estimated Fair Values of Warrant Measured on Recurring Basis Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Equity Securities Derivative liabilities Accumulated deficit [Accumulated deficit] Accounts payable Accrued salary Accrued interest Accrued liabilities Accounts Payable And Accrued Liabilities Award Date Axis Short Term Debt Type Axis originated in April 2018 [Member] Convertible Notes Payable [Member] Originated in June 2018 [Member] Originated in October 2018 [Member] Issued fiscal year 2022 [Member] Issued fiscal year 2023 [Member] Total convertible notes payable Less: Unamortized debt discount Total convertible notes Less: current portion of convertible notes EX-101.CAL 8 bdpt-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 9 bdpt-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 10 bdpt-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 11 bdpt_10qimg1.jpg begin 644 bdpt_10qimg1.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2023	Aug. 10, 2023
Cover [Abstract]
Entity Registrant Name	BioAdaptives Inc.
Entity Central Index Key	0001575142
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		776,464,023
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-54949
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	46-2592228
Entity Address Address Line 1	2620 Regatta Drive
Entity Address Address Line 2	Suite 102
Entity Address City Or Town	Las Vegas
Entity Address State Or Province	NV
Entity Address Postal Zip Code	89128
City Area Code	702
Local Phone Number	659-8829
Entity Interactive Data Current	Yes

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current Assets:
Cash	$ 40,121	$ 25,405
Marketable securities	21	42
Inventory	6,487	8,877
Total Current Assets	46,629	34,324
License and patent, net	1,644	2,990
TOTAL ASSETS	48,273	37,314
Current Liabilities:
Accounts payable and accrued liabilities	419,685	409,920
Derivative liabilities	930,072	686,856
Current portion of convertible notes - net of discount of $42,512 and $7,647	315,738	381,793
Note payable - related party	61,290	10,246
Total Current Liabilities	1,726,785	1,488,815
Total Liabilities	1,726,785	1,488,815
Stockholders' Deficit:
Common stock ($.0001 par value, 1,250,000,000 shares authorized; 576,474,023 and 252,554,765 shares issued and outstanding, and 10,000 issuable, respectively)	57,647	25,255
Additional paid-in capital	6,246,464	6,074,763
Accumulated deficit	(7,982,783)	(7,551,679)
Total Stockholders' Deficit	(1,678,512)	(1,451,501)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	48,273	37,314
Series A Preferred Stock [Member]
Stockholders' Deficit:
Preferred stock, ($.0001 par value, 10,000,000 shares authorized;	160	160
Series B Preferred Stock [Member]
Stockholders' Deficit:
Preferred stock, ($.0001 par value, 10,000,000 shares authorized;	$ 0	$ 0

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Convertible notes payable current, discount	$ 42,512	$ 7,647
Preferred stock, shares par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,250,000,000	1,250,000,000
Common stock, shares issued	576,474,023	252,554,765
Common stock, shares outstanding	576,474,023	252,554,765
Common stock, shares issuable	10,000	10,000
Series A Preferred Stock [Member]
Preferred stock, shares authorized	4,000,000	4,000,000
Preferred stock, shares issued	1,600,000	1,600,000
Preferred stock, shares outstanding	1,600,000	1,600,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)
Revenues	$ 2,339	$ 4,322	$ 5,715	$ 9,855
Cost of revenue	849	2,169	2,245	5,759
Gross Profit	1,490	2,153	3,470	4,096
Operating Expenses
General and administrative	14,516	87,517	26,552	192,717
Professional fees	42,246	34,112	50,496	71,944
Amortization of license and patent	677	23,821	1,346	56,988
Total Operating Expenses	57,439	145,450	78,394	321,649
Other Income (Expense)
Unrealized gain (loss) on marketable securities	(10)	(106)	(20)	(127)
Interest expense	(52,253)	(75,367)	(103,316)	(105,466)
Change in fair value of derivative liabilities	(35,705)	(5,067)	(252,844)	(167,822)
Total Other Expense	(87,968)	(80,540)	(356,180)	(273,415)
Loss before income taxes	(143,917)	(223,837)	(431,104)	(590,968)
Net Loss	$ (143,917)	$ (223,837)	$ (431,104)	$ (590,968)
Net Loss Per Common Share:
Basic and Diluted	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.01)
Weighted Average Number of Common Shares Outstanding:
Basic and Diluted	441,742,955	67,545,413	355,268,125	60,677,388

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT - USD ($)	Total	Series A Preferred Stocks	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Dec. 31, 2021		1,600,000	50,819,780
Balance, amount at Dec. 31, 2021	$ (1,093,039)	$ 160	$ 5,082	$ 5,557,828	$ (6,656,109)
Common stock issued for conversion of debt, shares			7,540,799
Common stock issued for conversion of debt, amount	52,017	0	$ 754	51,263	0
Debts forgiveness - related party	10,000	0	0	10,000	0
Net loss for the period	(367,131)	$ 0	$ 0	0	(367,131)
Balance, shares at Mar. 31, 2022		1,600,000	58,360,579
Balance, amount at Mar. 31, 2022	(1,398,153)	$ 160	$ 5,836	5,619,091	(7,023,240)
Balance, shares at Dec. 31, 2021		1,600,000	50,819,780
Balance, amount at Dec. 31, 2021	(1,093,039)	$ 160	$ 5,082	5,557,828	(6,656,109)
Debts forgiveness - related party	10,000
Net loss for the period	(590,968)
Warrant issued for acquisition of patent	5,429
Balance, shares at Jun. 30, 2022		1,600,000	77,457,483
Balance, amount at Jun. 30, 2022	(1,494,946)	$ 160	$ 7,746	5,744,225	(7,247,077)
Balance, shares at Mar. 31, 2022		1,600,000	58,360,579
Balance, amount at Mar. 31, 2022	(1,398,153)	$ 160	$ 5,836	5,619,091	(7,023,240)
Common stock issued for conversion of debt, shares			19,096,904
Common stock issued for conversion of debt, amount	121,615	0	$ 1,910	119,705	0
Net loss for the period	(223,837)	0	0	0	(223,837)
Warrant issued for acquisition of patent	5,429	$ 0	$ 0	5,429	0
Balance, shares at Jun. 30, 2022		1,600,000	77,457,483
Balance, amount at Jun. 30, 2022	(1,494,946)	$ 160	$ 7,746	5,744,225	(7,247,077)
Balance, shares at Dec. 31, 2022		1,600,000	252,554,765
Balance, amount at Dec. 31, 2022	(1,451,501)	$ 160	$ 25,255	6,074,763	(7,551,679)
Common stock issued for conversion of debt, shares			132,382,517
Common stock issued for conversion of debt, amount	108,036	0	$ 13,239	94,797	0
Net loss for the period	(287,187)	$ 0	$ 0	0	(287,187)
Balance, shares at Mar. 31, 2023		1,600,000	384,937,282
Balance, amount at Mar. 31, 2023	(1,630,652)	$ 160	$ 38,494	6,169,560	(7,838,866)
Balance, shares at Dec. 31, 2022		1,600,000	252,554,765
Balance, amount at Dec. 31, 2022	(1,451,501)	$ 160	$ 25,255	6,074,763	(7,551,679)
Debts forgiveness - related party	0
Net loss for the period	(431,104)
Warrant issued for acquisition of patent	0
Balance, shares at Jun. 30, 2023		1,600,000	576,474,023
Balance, amount at Jun. 30, 2023	(1,678,512)	$ 160	$ 57,647	6,246,464	(7,982,783)
Balance, shares at Mar. 31, 2023		1,600,000	384,937,282
Balance, amount at Mar. 31, 2023	(1,630,652)	$ 160	$ 38,494	6,169,560	(7,838,866)
Common stock issued for conversion of debt, shares			191,536,741
Common stock issued for conversion of debt, amount	96,057	0	$ 19,153	76,904	0
Net loss for the period	(143,917)	$ 0	$ 0	0	(143,917)
Balance, shares at Jun. 30, 2023		1,600,000	576,474,023
Balance, amount at Jun. 30, 2023	$ (1,678,512)	$ 160	$ 57,647	$ 6,246,464	$ (7,982,783)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (431,104)	$ (590,968)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative liabilities	252,844	162,755
Amortization of license and patent	1,346	56,988
Amortization of debt discount	82,385	79,547
Unrealized (gain) loss on investments in marketable securities	21	127
Changes in operating assets and liabilities:
Inventory	2,390	(5,897)
Accounts payable and accrued liabilities	15,790	157,431
Due to related party	0	1,803
Net Cash Used in Operating Activities	(76,328)	(138,214)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceed from related party	51,044	1,623
Repayment to related party	0	(1,623)
Repayment of notes payable - related party	0	(25,272)
Proceeds from convertible notes	40,000	125,000
Net Cash Provided by Financing Activities	91,044	99,728
Net change in cash	14,716	(38,486)
Cash at beginning of period	25,405	82,936
Cash at end of period	40,121	44,450
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	0	0
Cash paid for interest	0	4,728
NON-CASH INVESTING AND FINANCING ACTIVITIES
Derivative liability recognized as debt discount	110,000	92,000
Issuance of common stock for conversion of debt	204,093	173,632
Debts forgiveness - related party	0	10,000
Warrant issued for Patent's acquisition	$ 0	$ 5,429

XML 18 R7.htm IDEA: XBRL DOCUMENT

DESCRIPTION OF BUSINESS AND HISTORY

6 Months Ended

Jun. 30, 2023

DESCRIPTION OF BUSINESS AND HISTORY

1. DESCRIPTION OF BUSINESS AND HISTORY

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business

The Company’s corporate office is located at 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128.

XML 19 R8.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT POLICIES

6 Months Ended

Jun. 30, 2023

SUMMARY OF SIGNIFICANT POLICIES

2. SUMMARY OF SIGNIFICANT POLICIES

2. SUMMARY OF SIGNIFICANT POLICIES

Basis of Presentation

Use of estimates

Earnings (loss) per share

Financial Instruments and Fair Value Measurements

The following table summarizes fair value measurements by level as of June 30, 2023, and December 31, 2022, measured at fair value on a recurring basis:

	Total Carrying Value		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	as of June 30, 2023		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities	$	21	$	21	$	-	$	-

Liabilities
Derivative liabilities	$	930,072	$	-	$	-	$	930,072

	Fair Value Measurements as of December 31, 2022, Using:
	Total Carrying Value as of December 31,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2022		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities, 105,736 shares of common stock of Hemp, Inc. (HEMP)	$	42	$	42	$	-	$	-

Liabilities
Derivative liabilities	$	686,856	$	-	$	-	$	686,856

Derivative Financial Instruments

XML 20 R9.htm IDEA: XBRL DOCUMENT

GOING CONCERN

6 Months Ended

Jun. 30, 2023

GOING CONCERN

3. GOING CONCERN

3. GOING CONCERN

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

XML 21 R10.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

6 Months Ended

Jun. 30, 2023

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities aa of June 30, 2023 and December 31, 2022, consists of the following:

	June 30,		December 31,
	2023		2022
Accounts payable	$	1,394	$	6,939
Accrued salary		300,000		300,000
Accrued interest		116,872		101,966
Accrued liabilities		1,419		1,015
	$	419,685	$	409,920

XML 22 R11.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES

6 Months Ended

Jun. 30, 2023

CONVERTIBLE NOTES

5. CONVERTIBLE NOTES

5. CONVERTIBLE NOTES

Convertible notes as of June 30, 2023 and December 31, 2022, consist of the following:

	June 30,			December 31,
	2023			2022
Convertible Notes - originated in April 2018	$	95,000		$	95,000
Convertible Notes - originated in June 2018		166,000			166,000
Convertible Notes - originated in October 2018		50,000			50,000
Convertible Notes - issued fiscal year 2022		-			78,440
Convertible Notes - issued fiscal year 2023		47,250			-
Total convertible notes payable		358,250			389,440

Less: Unamortized debt discount		(42,512	)		(7,647	)
Total convertible notes		315,738			381,793

Less: current portion of convertible notes		315,738			381,793
Long-term convertible notes	$	-		$	-

Conversion

Convertible Notes – Issued during the year ended December 31, 2018

	·	Term two years;

	·	Annual interest rates 12%;

	·	Convertible at the option of the holders at any time

	·	Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price.

Convertible Notes - Issued during the year ended December 31, 2021

	·	Term one year;

	·	Annual interest rates 10%;

	·	Convertible at 180 days from issuance

	·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

During the year ended December 31, 2021, the Company converted principal of $172,050 and accrued interest of $6,200 into 17,787,355 shares of common stock.

Convertible Notes - Issued during the year ended December 31, 2022

	·	Term one year;

	·	Annual interest rates 10%;

	·	Convertible at 180 days from issuance

	·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

Convertible Notes - Issued during the year ended December 31, 2023

	·	Term one year;

	·	Annual interest rates 10%;

	·	Convertible at any time

	·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES

6 Months Ended

Jun. 30, 2023

DERIVATIVE LIABILITIES

6. DERIVATIVE LIABILITIES

6. DERIVATIVE LIABILITIES

Fair Value Assumptions Used in Accounting for Derivative Liabilities.

ASC 815 requires we assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item.

For the six months ended June 30, 2023, and the year ended December 31, 2022, the estimated fair values of the liabilities measured on a recurring basis are as follows:

	Six months ended		Year ended
	June 30,		December 31,
	2023		2021
Expected term	0.18- 1.00 years		0.06 - 0.51 years
Expected average volatility	141% - 240%		72% - 164%
Expected dividend yield		-		-
Risk-free interest rate	4.76% - 5.50%		0.17% - 4.72%

The following table summarizes the changes in the derivative liabilities during the six months ended June 30, 2023.

Fair Value Measurements Using Significant Observable Inputs (Level 3)

Balance - December 31, 2022	$	686,856

Addition of new derivatives recognized as debt discounts		110,000
Addition of new derivatives recognized as loss on derivatives		459,854
Settled on issuance of common stock		(119,628	)
(Gain) loss on change in fair value of the derivative		(207,010	)
Balance - June 30, 2023	$	930,072

The aggregate (gain) loss on derivatives during the six months ended June 30, 2023, and 2022 was as follows.

	Six months ended
	June 30,
	2023			2022
Day one loss due to derivative liabilities on convertible notes	$	459,854		$	28,960
(Gain) loss on change in fair value of the derivative liabilities		(207,010	)		138,862
	$	252,844		$	167,822

XML 24 R13.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY

6 Months Ended

Jun. 30, 2023

STOCKHOLDERS EQUITY

7. STOCKHOLDERS' EQUITY

7. STOCKHOLDERS’ EQUITY

Preferred Stock

Series A Preferred Stock

There are 1,600,000 shares of Series A shares issued as of the date of this filing.

Series B Preferred Stock

As of the date of this filing, no shares of Series B Preferred Stock are issued and outstanding.

Common Stock

On March 7, 2023, the Company amended its articles of incorporation to increase its authorized common shares from 750,000,000 to 1,250,000,000; this increase will be effective March 27, 2023.

Fiscal year 2023

During the six months ended June 30, 2023, the Company issued 323,919,258 shares of common stock valued at $204,093 for conversion of debt.

Warrant

The estimated fair values of the warrant are as follows:

	Year Ended
	December 31,
	2022
Expected term	2.00 years
Expected average volatility		235	%
Expected dividend yield		-
Risk-free interest rate		1.31	%

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

6 Months Ended

Jun. 30, 2023

RELATED PARTY TRANSACTIONS

8. RELATED PARTY TRANSACTIONS

8. RELATED PARTY TRANSACTIONS

Notes payable – related party

During the six months ended June 30, 2023 and 2022, the Company repaid notes payable to a related party and accrued interest of $0 and $30,000 and recognized interest of $168 and $363, respectively.

Due to related party

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2023

SUBSEQUENT EVENTS

9. SUBSEQUENT EVENTS

9. SUBSEQUENT EVENTS

XML 27 R16.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT POLICIES (Policies)

6 Months Ended

Jun. 30, 2023

SUMMARY OF SIGNIFICANT POLICIES

Basis of presentation

Use of estimates

Earnings (loss) per share

Financial Instruments and Fair Value Measurements

The following table summarizes fair value measurements by level as of June 30, 2023, and December 31, 2022, measured at fair value on a recurring basis:

	Total Carrying Value		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	as of June 30, 2023		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities	$	21	$	21	$	-	$	-

Liabilities
Derivative liabilities	$	930,072	$	-	$	-	$	930,072

	Fair Value Measurements as of December 31, 2022, Using:
	Total Carrying Value as of December 31,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2022		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities, 105,736 shares of common stock of Hemp, Inc. (HEMP)	$	42	$	42	$	-	$	-

Liabilities
Derivative liabilities	$	686,856	$	-	$	-	$	686,856

Derivative Financial Instruments

XML 28 R17.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT POLICIES (Tables)

6 Months Ended

Jun. 30, 2023

SUMMARY OF SIGNIFICANT POLICIES

Schedule of Fair Value of Measurements of Assets on Recurring Basis

	Total Carrying Value		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	as of June 30, 2023		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities	$	21	$	21	$	-	$	-

Liabilities
Derivative liabilities	$	930,072	$	-	$	-	$	930,072

	Fair Value Measurements as of December 31, 2022, Using:
	Total Carrying Value as of December 31,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2022		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities, 105,736 shares of common stock of Hemp, Inc. (HEMP)	$	42	$	42	$	-	$	-

Liabilities
Derivative liabilities	$	686,856	$	-	$	-	$	686,856

XML 29 R18.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

6 Months Ended

Jun. 30, 2023

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Schedule of Accounts Payable and Accrued Liabilities

	June 30,		December 31,
	2023		2022
Accounts payable	$	1,394	$	6,939
Accrued salary		300,000		300,000
Accrued interest		116,872		101,966
Accrued liabilities		1,419		1,015
	$	419,685	$	409,920

XML 30 R19.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES (Tables)

6 Months Ended

Jun. 30, 2023

CONVERTIBLE NOTES

Schedule of Convertible Notes

	June 30,			December 31,
	2023			2022
Convertible Notes - originated in April 2018	$	95,000		$	95,000
Convertible Notes - originated in June 2018		166,000			166,000
Convertible Notes - originated in October 2018		50,000			50,000
Convertible Notes - issued fiscal year 2022		-			78,440
Convertible Notes - issued fiscal year 2023		47,250			-
Total convertible notes payable		358,250			389,440

Less: Unamortized debt discount		(42,512	)		(7,647	)
Total convertible notes		315,738			381,793

Less: current portion of convertible notes		315,738			381,793
Long-term convertible notes	$	-		$	-

XML 31 R20.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Tables)

6 Months Ended

Jun. 30, 2023

DERIVATIVE LIABILITIES

Schedule of Estimated Fair Values of Liabilities Measured on Recurring Basis

	Six months ended		Year ended
	June 30,		December 31,
	2023		2021
Expected term	0.18- 1.00 years		0.06 - 0.51 years
Expected average volatility	141% - 240%		72% - 164%
Expected dividend yield		-		-
Risk-free interest rate	4.76% - 5.50%		0.17% - 4.72%

Summary of Changes in Derivative Liabilities

Fair Value Measurements Using Significant Observable Inputs (Level 3)

Balance - December 31, 2022	$	686,856

Addition of new derivatives recognized as debt discounts		110,000
Addition of new derivatives recognized as loss on derivatives		459,854
Settled on issuance of common stock		(119,628	)
(Gain) loss on change in fair value of the derivative		(207,010	)
Balance - June 30, 2023	$	930,072

Schedule of (gain) loss on Derivatives

	Six months ended
	June 30,
	2023			2022
Day one loss due to derivative liabilities on convertible notes	$	459,854		$	28,960
(Gain) loss on change in fair value of the derivative liabilities		(207,010	)		138,862
	$	252,844		$	167,822

XML 32 R21.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Tables)

6 Months Ended

Jun. 30, 2023

STOCKHOLDERS EQUITY

Schedule of Estimated Fair Values of Warrant Measured on Recurring Basis

	Year Ended
	December 31,
	2022
Expected term	2.00 years
Expected average volatility		235	%
Expected dividend yield		-
Risk-free interest rate		1.31	%

XML 33 R22.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT POLICIES (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Equity Securities	$ 21	$ 42
Derivative liabilities	930,072	686,856
Fair Value, Inputs, Level 1 [Member]
Equity Securities	21	42
Derivative liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Equity Securities	0	0
Derivative liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Equity Securities	0	0
Derivative liabilities	$ 930,072	$ 686,856

XML 34 R23.htm IDEA: XBRL DOCUMENT

GOING CONCERN (Details Narrative)	Jun. 30, 2023 USD ($)
GOING CONCERN
Accumulated deficit	$ (7,982,783)

XML 35 R24.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable	$ 1,394	$ 6,939
Accrued salary	300,000	300,000
Accrued interest	116,872	101,966
Accrued liabilities	1,419	1,015
Accounts Payable And Accrued Liabilities	$ 419,685	$ 409,920

XML 36 R25.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Total convertible notes payable	$ 358,250	$ 389,440
Less: Unamortized debt discount	(42,512)	(7,647)
Total convertible notes	315,738	381,793
Less: current portion of convertible notes	315,738	381,793
Long-term convertible notes	0	0
originated in April 2018 [Member] \| Convertible Notes Payable [Member]
Total convertible notes payable	95,000	95,000
Originated in June 2018 [Member] \| Convertible Notes Payable [Member]
Total convertible notes payable	166,000	166,000
Originated in October 2018 [Member] \| Convertible Notes Payable [Member]
Total convertible notes payable	50,000	50,000
Issued fiscal year 2022 [Member] \| Convertible Notes Payable [Member]
Total convertible notes payable	0	78,440
Issued fiscal year 2023 [Member] \| Convertible Notes Payable [Member]
Total convertible notes payable	$ 47,250	$ 0

XML 37 R26.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
CONVERTIBLE NOTES (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2018
Debt discount	$ 117,250
Derivative loss	459,854
Amortization of debt discount	82,385	$ 79,547
Interest expenses	20,763	$ 25,556
Settled on issuance of common stock	64,258
Value Assigned of derivatives liabilities	569,854
Accrued interest	115,656		$ 100,919
Principal amount of convertible notes	78,440
Accrued interest of convertible notes	$ 6,026
Convertible shares of common stock	323,919,258
Accrued interest	$ 1,419		1,015
Convertible Notes Payable [Member]
Principal amount of convertible notes	$ 47,250		$ 211,500	$ 222,500	$ 426,000
Description of conversion price	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date		Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date	Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price
Proceeds from Convertible notes	$ 40,000		$ 195,000	$ 205,000	$ 426,000
Debt instrument converted amount					$ 22,210
Debt instrument converted amount shares issued				17,787,355	107,000
Convertible debt term	1 year			1 year	2 years
Annual interest rates	10.00%			10.00%	12.00%
Debt Instrument, Convertible, Terms of Conversion Feature	Convertible at any time		Convertible at 180 days from issuance	Convertible at 180 days from issuance	Convertible at the option of the holders at any time
Unpaid principal amount				$ 172,050
Accrued interest				$ 6,200

XML 38 R27.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Details)	6 Months Ended	12 Months Ended
DERIVATIVE LIABILITIES (Details)	Jun. 30, 2023	Dec. 31, 2021
Expected dividend yield	0.00%	0.00%
Expected average volatility	235.00%
Risk-free interest rate	1.31%
Minimum [Member]
Expected term	2 months 4 days	21 days
Expected average volatility	141.00%	72.00%
Risk-free interest rate	4.76%	0.17%
Maximum [Member]
Expected term	1 year	6 months 3 days
Expected average volatility	240.00%	164.00%
Risk-free interest rate	5.50%	4.72%

XML 39 R28.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Details 1) - USD ($)	6 Months Ended
DERIVATIVE LIABILITIES (Details 1) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
DERIVATIVE LIABILITIES
Beginnig Balance	$ 686,856
Addition of new derivatives recognized as debt discounts	110,000
Addition of new derivatives recognized as loss on derivatives	459,854
Settled on issuance of common stock	(119,628)
Loss on change in fair value of the derivative	(207,010)	$ 138,862
Ending Balance	$ 930,072

XML 40 R29.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Details 2) - USD ($)	6 Months Ended
DERIVATIVE LIABILITIES (Details 2) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
DERIVATIVE LIABILITIES
Day one loss due to derivative liabilities on convertible notes	$ 459,854	$ 28,960
(Gain) loss on change in fair value of the derivative liabilities	(207,010)	138,862
Aggregate (gain) loss on derivatives	$ 252,844	$ 167,822

XML 41 R30.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Details)	6 Months Ended
STOCKHOLDERS EQUITY (Details)	Jun. 30, 2023
STOCKHOLDERS EQUITY
Expected term	2 years
Expected average volatility	235.00%
Expected dividend yield	0.00%
Risk-free interest rate	1.31%

XML 42 R31.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)			1 Months Ended	6 Months Ended
STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	Feb. 06, 2022	Feb. 06, 2020	Jan. 24, 2022	Jun. 30, 2023	Jun. 30, 2022	Mar. 07, 2023	Dec. 31, 2022	Nov. 30, 2022
Preferred stock, shares authorized			10,000,000	10,000,000			10,000,000
Shares Issued of common stock				323,919,258
Conversion of debt				$ 204,093
Common stock, shares outstanding				576,474,023			252,554,765
Common stock, shares authorized				1,250,000,000		1,250,000,000	1,250,000,000	200,000,000
Exercise price	$ 0.006
Common stock, shares issuable				10,000			10,000
Fair value of shares granted	$ 5,429			$ 252,844	$ 162,755
Preferred stock, shares par value				$ 0.0001			$ 0.0001
Series A Preferred Stock [Member]
Preferred stock, shares authorized				4,000,000			4,000,000
Preferred stock, shares authorized		4,000,000	5,000,000	4,000,000
Preferred stock, shares par value		$ 0.001	$ 0.0001
Conversion common rights		at a 5:1 ratio
Preferred stock, shares issued				1,600,000			1,600,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized			6,000,000	6,000,000			6,000,000
Preferred stock, shares par value			$ 0.001
Conversion common rights			at a 10:1 ratio
Preferred stock, shares issued				0			0
Common Stocks [Member]
Common stock, shares outstanding				576,474,023			252,544,765
Common stock, shares authorized						750,000,000
Common stock, shares granted	1,000,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Rate of interest	4.00%
Repayment of notes payable - related party	$ 0	$ 30,000
Notes payable- related party noncurrent	8,444		$ 8,444
Interest amount	168	363
Notes payable - accrued interest	1,214		$ 1,047
Dr. Edward E. Jacobs [Member]
Due to related parties	52,846	$ 1,802
Advances to related party	$ 51,044

XML 44 R33.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENT (Details Narrative) - USD ($)	Jun. 30, 2023	Mar. 07, 2023	Dec. 31, 2022	Nov. 30, 2022
SUBSEQUENT EVENT (Details Narrative)
Common stock, shares authorized	1,250,000,000	1,250,000,000	1,250,000,000	200,000,000
Common stock par value	$ 0.0001		$ 0.0001	$ 0.001
Amount receive from initial wholesale order				$ 9,000

XML 45 bdpt_10q_htm.xml IDEA: XBRL DOCUMENT 0001575142 2023-01-01 2023-06-30 0001575142 2022-11-30 0001575142 bdpt:DrEdwardeJacobsMember 2023-06-30 0001575142 bdpt:DrEdwardeJacobsMember 2022-01-01 2022-06-30 0001575142 bdpt:DrEdwardeJacobsMember 2023-01-01 2023-06-30 0001575142 us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-01-24 0001575142 us-gaap:SeriesAPreferredStockMember 2020-02-01 2020-02-06 0001575142 2022-02-01 2022-02-06 0001575142 bdpt:CommonStocksMember 2022-02-06 0001575142 bdpt:CommonStocksMember 2023-03-07 0001575142 2023-03-07 0001575142 bdpt:CommonStocksMember 2022-12-31 0001575142 bdpt:CommonStocksMember 2023-06-30 0001575142 us-gaap:SeriesAPreferredStockMember 2020-02-06 0001575142 us-gaap:SeriesBPreferredStockMember 2022-01-24 0001575142 us-gaap:SeriesAPreferredStockMember 2022-01-24 0001575142 2022-01-24 0001575142 srt:MaximumMember 2021-01-01 2021-12-31 0001575142 srt:MinimumMember 2021-01-01 2021-12-31 0001575142 srt:MaximumMember 2023-01-01 2023-06-30 0001575142 srt:MinimumMember 2023-01-01 2023-06-30 0001575142 2021-01-01 2021-12-31 0001575142 us-gaap:ConvertibleNotesPayableMember 2021-12-31 0001575142 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-12-31 0001575142 us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-06-30 0001575142 us-gaap:ConvertibleNotesPayableMember 2018-01-01 2018-12-31 0001575142 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-12-31 0001575142 bdpt:IssuedFiscalYearTwoThousandTwentyThreeMember us-gaap:ConvertibleNotesPayableMember 2023-06-30 0001575142 bdpt:IssuedFiscalYearTwoThousandTwentyThreeMember us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001575142 bdpt:IssuedFiscalYearTwoThousandTwentyTwoMember us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001575142 bdpt:IssuedFiscalYearTwoThousandTwentyTwoMember us-gaap:ConvertibleNotesPayableMember 2023-06-30 0001575142 bdpt:OriginatedInOctoberTwoThousandEighteenMember us-gaap:ConvertibleNotesPayableMember 2023-06-30 0001575142 bdpt:OriginatedInOctoberTwoThousandEighteenMember us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001575142 bdpt:OriginatedInJuneTwoThousandEighteenMember us-gaap:ConvertibleNotesPayableMember 2023-06-30 0001575142 bdpt:OriginatedInJuneTwoThousandEighteenMember us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001575142 bdpt:OriginatedInAprilTwoThousandEighteenMember us-gaap:ConvertibleNotesPayableMember 2023-06-30 0001575142 bdpt:OriginatedInAprilTwoThousandEighteenMember us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001575142 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001575142 us-gaap:FairValueInputsLevel2Member 2023-06-30 0001575142 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001575142 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001575142 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001575142 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001575142 us-gaap:RetainedEarningsMember 2023-06-30 0001575142 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001575142 us-gaap:CommonStockMember 2023-06-30 0001575142 bdpt:SeriesAPreferredStocksMember 2023-06-30 0001575142 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001575142 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001575142 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001575142 bdpt:SeriesAPreferredStocksMember 2023-04-01 2023-06-30 0001575142 2023-03-31 0001575142 us-gaap:RetainedEarningsMember 2023-03-31 0001575142 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001575142 us-gaap:CommonStockMember 2023-03-31 0001575142 bdpt:SeriesAPreferredStocksMember 2023-03-31 0001575142 2023-01-01 2023-03-31 0001575142 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001575142 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001575142 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001575142 bdpt:SeriesAPreferredStocksMember 2023-01-01 2023-03-31 0001575142 us-gaap:RetainedEarningsMember 2022-12-31 0001575142 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001575142 us-gaap:CommonStockMember 2022-12-31 0001575142 bdpt:SeriesAPreferredStocksMember 2022-12-31 0001575142 2022-06-30 0001575142 us-gaap:RetainedEarningsMember 2022-06-30 0001575142 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001575142 us-gaap:CommonStockMember 2022-06-30 0001575142 bdpt:SeriesAPreferredStocksMember 2022-06-30 0001575142 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001575142 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001575142 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001575142 bdpt:SeriesAPreferredStocksMember 2022-04-01 2022-06-30 0001575142 2022-03-31 0001575142 us-gaap:RetainedEarningsMember 2022-03-31 0001575142 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001575142 us-gaap:CommonStockMember 2022-03-31 0001575142 bdpt:SeriesAPreferredStocksMember 2022-03-31 0001575142 2022-01-01 2022-03-31 0001575142 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001575142 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001575142 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001575142 bdpt:SeriesAPreferredStocksMember 2022-01-01 2022-03-31 0001575142 2021-12-31 0001575142 us-gaap:RetainedEarningsMember 2021-12-31 0001575142 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001575142 us-gaap:CommonStockMember 2021-12-31 0001575142 bdpt:SeriesAPreferredStocksMember 2021-12-31 0001575142 2022-01-01 2022-06-30 0001575142 2022-04-01 2022-06-30 0001575142 2023-04-01 2023-06-30 0001575142 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001575142 us-gaap:SeriesBPreferredStockMember 2023-06-30 0001575142 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001575142 us-gaap:SeriesAPreferredStockMember 2023-06-30 0001575142 2022-12-31 0001575142 2023-06-30 0001575142 2023-08-10 iso4217:USD shares iso4217:USD shares pure 0001575142 false --12-31 Q2 2023 true false

0.0001

10000000

4000000

6000000

0.0001

1250000000

252554765

576474023

10000

1600000

P1Y

P2Y

10-Q 2023-06-30 000-54949 BioAdaptives Inc. DE 46-2592228 2620 Regatta Drive Suite 102 Las Vegas NV 89128 702 659-8829 Yes Yes Non-accelerated Filer true false false 776464023

40121

25405

6487

8877

46629

34324

1644

2990

48273

37314

419685

409920

930072

686856

42512

7647

315738

381793

61290 10246

1726785

1488815

1726785

1488815

0.0001

10000000

4000000

1600000

160

6000000

0.0001

1250000000

576474023

252554765

10000

57647

25255

6246464

6074763

-7982783

-7551679

-1678512

-1451501

48273

37314

2339

4322

5715

9855

849

2169

2245

5759

1490

2153

3470

4096

14516

87517

26552

192717

42246

34112

50496

71944

677

23821

1346

56988

57439

145450

78394

321649

-10

-106

-20

-127

52253

75367

103316

105466

-35705

-5067

-252844

-167822

-87968

-80540

-356180

-273415

-143917

-223837

-431104

-590968

-143917

-223837

-431104

-590968

-0.00 -0.00 -0.00 -0.01

441742955

67545413

355268125

60677388

1600000

160

252554765

25255

6074763

-7551679

-1451501

132382517

13239

94797

108036

-287187

1600000

160

384937282

38494

6169560

-7838866

-1630652

191536741

19153

76904

96057

-143917

1600000

160

576474023

57647

6246464

-7982783

-1678512

1600000

160

50819780

5082

5557828

-6656109

-1093039

7540799

754

51263

52017

0 0 10000 0 10000

-367131

1600000

160

58360579

5836

5619091

-7023240

-1398153

19096904

1910

119705

121615

5429

-223837

1600000

160

77457483

7746

5744225

-7247077

-1494946

431104

590968

252844

162755

1346

56988

82385

79547

-21 -127

-2390

5897

15790

157431

1803

-76328

-138214

51044

1623

25272

40000

125000

91044

99728

14716

-38486

25405

82936

40121

44450

4728

110000

92000

204093

173632

0 10000

5429

1. DESCRIPTION OF BUSINESS AND HISTORY Description of business BioAdaptives, Inc. (“BioAdaptives” or the “Company”) was incorporated in Delaware on April 19, 2013, under the name Apex 8, Inc. Shortly afterwards, the Company’s control person sold his interest; new owners appointed management and changed its name to BioAdaptives, Inc. The Company acquired assets relating to the investigation, development and marketing of nutraceutical products; equipment designed to improve the bioavailability of nutrients in humans and animals; and licenses for specific products. We commenced investigation of the role of various botanicals in primitive cell development and proliferation, including certain algae along with herbs used in Traditional Chinese Medicine and Ayurvedic Practice. In the course of this investigation, BioAdaptives identified several potential human and animal products. The Company terminated further work on the equipment and products licensed in its early stages to concentrate on these products, for both human and animals. The Company’s current nutraceutical products are natural plant- and algal-based dietary supplements for humans and animals developed with our knowledge of natural foods. Our product lines include PluriCell®, PluriPain®, and PrimiLung™ for humans along with Equine All-in-One™ and a related Booster for horses. Our human products are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness. The science behind our products has proven to be effective for performance enhancement and pain relief for horses and dogs as well as providing improvements in appearance and we have developed products to utilize these advances. The Company also markets the Lung Cleanser™ medical device, which is sold with our PrimiLung® product as part of a Lung Armor™ package. Additionally, during this reporting period, the Company acquired patent rights to a method to embed oxygen in water and is developing commercial products based on this technology that will augment and complement our current product lines. All of these products are sold under licensing and manufacturing agreements with third parties and our current activities are reliant on marketing and distributing products developed and owned by others. In February 2022, the Company acquired US Patent rights to a process that increases dissolved oxygen in water. The process produces MorO2, ingestion of which is believed to increase diffusion of oxygen into muscle tissues. The Company is developing a business plan to manufacture and market products based on the MorO2 technology. The Company’s corporate office is located at 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128.

2. SUMMARY OF SIGNIFICANT POLICIES Basis of Presentation The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10K. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim period presented, have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10K filed with SEC on June 30, 2023, have been omitted.Use of estimates The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates. Earnings (loss) per share Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued. Financial Instruments and Fair Value Measurements As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The following table summarizes fair value measurements by level as of June 30, 2023, and December 31, 2022, measured at fair value on a recurring basis: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Total Carrying Value </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Quoted Market Prices in Active Markets</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Significant Other Observable Inputs</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Significant Unobservable Inputs</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">as of June 30, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Assets:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity Securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">930,072</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">930,072</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value Measurements as of December 31, 2022, Using:</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">TotalCarryingValueas ofDecember 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">QuotedMarketPrices inActiveMarkets</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">SignificantOtherObservableInputs</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Significant UnobservableInputs</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Assets:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity Securities, 105,736 shares of common stock of Hemp, Inc. (HEMP)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">42</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">42</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">686,856</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">686,856</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used a Black Scholes valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Financial Statements filed with the SEC on Form 10K. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim period presented, have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10K filed with SEC on June 30, 2023, have been omitted.

The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued.

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The following table summarizes fair value measurements by level as of June 30, 2023, and December 31, 2022, measured at fair value on a recurring basis: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Total Carrying Value </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Quoted Market Prices in Active Markets</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Significant Other Observable Inputs</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Significant Unobservable Inputs</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">as of June 30, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Assets:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity Securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">930,072</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">930,072</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value Measurements as of December 31, 2022, Using:</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">TotalCarryingValueas ofDecember 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">QuotedMarketPrices inActiveMarkets</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">SignificantOtherObservableInputs</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Significant UnobservableInputs</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Assets:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity Securities, 105,736 shares of common stock of Hemp, Inc. (HEMP)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">42</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">42</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">686,856</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">686,856</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Total Carrying Value </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Quoted Market Prices in Active Markets</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Significant Other Observable Inputs</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Significant Unobservable Inputs</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">as of June 30, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Assets:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity Securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">930,072</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">930,072</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Fair Value Measurements as of December 31, 2022, Using:</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">TotalCarryingValueas ofDecember 31,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">QuotedMarketPrices inActiveMarkets</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">SignificantOtherObservableInputs</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Significant UnobservableInputs</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 1)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 2)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">(Level 3)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Assets:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Equity Securities, 105,736 shares of common stock of Hemp, Inc. (HEMP)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">42</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">42</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Derivative liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">686,856</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">686,856</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

930072

686856

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used a Black Scholes valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

3. GOING CONCERN The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $7,982,783 as of June 30, 2023. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. Obtaining additional financing, successful development of the Company’s contemplated plan of operations, and the transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties. In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

-7982783

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts payable and accrued liabilities aa of June 30, 2023 and December 31, 2022, consists of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">June 30,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,394</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,939</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accrued salary</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accrued interest</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116,872</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">101,966</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accrued liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,419</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,015</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">419,685</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">409,920</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

1394

6939

300000

116872 101966

1419

1015

419685

409920

5. CONVERTIBLE NOTES Convertible notes as of June 30, 2023 and December 31, 2022, consist of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">June 30,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Convertible Notes - originated in April 2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Convertible Notes - originated in June 2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">166,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">166,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Convertible Notes - originated in October 2018</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Convertible Notes - issued fiscal year 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">78,440</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Convertible Notes - issued fiscal year 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">47,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total convertible notes payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">358,250</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">389,440</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less: Unamortized debt discount</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(42,512</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,647</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total convertible notes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">315,738</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">381,793</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less: current portion of convertible notes</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">315,738</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">381,793</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Long-term convertible notes</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> For the six months ended June 30, 2023 and 2022, the interest expense on convertible notes was $20,763 and $25,556, respectively. As of June 30, 2023 and December 31, 2022, the accrued interest was $115,656 and $100,919, respectively. The Company recognized amortization expense related to the debt discount of $82,385 and $79,547 for the six months ended June 30, 2023 and 2022, respectively, which is included in interest expense in the statements of operation. Conversion During the six months ended June 30, 2023, the Company converted notes with principal amounts of $78,440 and accrued interest of $6,026 into 323,919,258 shares of common stock. The corresponding derivative liability at the date of conversion of $64,258 was credited to additional paid in capital. Convertible Notes – Issued during the year ended December 31, 2018 During the year ended December 31, 2018, the Company issued a total principal amount of $426,000 in convertible notes for cash proceeds of $426,000. The convertible notes were also provided with a total of 107,000 common shares valued at $22,210. The terms of these convertible notes are summarized as follows: <table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Term two years;</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Annual interest rates 12%;</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Convertible at the option of the holders at any time</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price.</td></tr></tbody></table> Convertible Notes - Issued during the year ended December 31, 2021 During the year ended December 31, 2021, the Company issued a total principal amount of $222,500 in convertible note for cash proceeds of $205,000. The terms of convertible note are summarized as follows: <table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Term one year;</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Annual interest rates 10%;</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Convertible at 180 days from issuance</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.</td></tr></tbody></table>During the year ended December 31, 2021, the Company converted principal of $172,050 and accrued interest of $6,200 into 17,787,355 shares of common stock. Convertible Notes - Issued during the year ended December 31, 2022 During the year ended December 31, 2022, the Company issued a total principal amount of $211,500 in convertible notes for cash proceeds of $195,000. The terms of convertible notes are summarized as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Term one year;</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Annual interest rates 10%;</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Convertible at 180 days from issuance</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.</td></tr></tbody></table> Convertible Notes - Issued during the year ended December 31, 2023 During the six months ended June 30, 2023, the Company issued a total principal amount of $47,250 in convertible notes for cash proceeds of $40,000. The terms of convertible notes are summarized as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Term one year;</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Annual interest rates 10%;</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Convertible at any time</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.</td></tr></tbody></table> The Company valued the conversion feature using the Black-Scholes pricing model. The fair value of the derivative liability for all the notes that became convertible, including the notes issued in prior years, during the six months ended June 30, 2023, amounted to $569,854, and $117,250 of the value assigned to the derivative liability was recognized as a debt discount to the notes while the balance of $459,854 was recognized as a “day 1” derivative loss.

95000 95000 166000 166000 50000 50000 0 78440 47250 0 358250 389440

42512

7647

315738

381793

315738

381793

20763

25556

115656 100919 82385 79547

78440

6026

323919258

64258

426000

107000

22210

0.12

Convertible at the option of the holders at any time

Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price

222500

205000

0.10

Convertible at 180 days from issuance

Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date

172050

6200

17787355

211500

195000

Convertible at 180 days from issuance

Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date

47250

40000

0.10

Convertible at any time

Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date

569854 117250 459854

6. DERIVATIVE LIABILITIES The Company analyzed the conversion option for derivative accounting consideration under ASC 815, Derivatives and Hedging, and hedging, and determined that the instrument should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The Company accounts for warrants as a derivative liability due to there being no explicit limit to the number of shares to be delivered upon settlement of all conversion options. Fair Value Assumptions Used in Accounting for Derivative Liabilities. ASC 815 requires we assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item.The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of June 30, 2023. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note is estimated using the Black-Scholes valuation model. For the six months ended June 30, 2023, and the year ended December 31, 2022, the estimated fair values of the liabilities measured on a recurring basis are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Six months ended </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Year ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">June 30,</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Expected term</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> 0.18- 1.00 years </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> 0.06 - 0.51 years </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">Expected average volatility</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">141% - 240%</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">72% - 164%</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividend yield</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">4.76% - 5.50%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">0.17% - 4.72%</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> The following table summarizes the changes in the derivative liabilities during the six months ended June 30, 2023. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Fair Value Measurements Using Significant Observable Inputs (Level 3)</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance - December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">686,856</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Addition of new derivatives recognized as debt discounts</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Addition of new derivatives recognized as loss on derivatives</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">459,854</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Settled on issuance of common stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(119,628</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">(Gain) loss on change in fair value of the derivative</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(207,010</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance - June 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">930,072</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The aggregate (gain) loss on derivatives during the six months ended June 30, 2023, and 2022 was as follows. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;">Six months ended </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Day one loss due to derivative liabilities on convertible notes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">459,854</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,960</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">(Gain) loss on change in fair value of the derivative liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(207,010</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">138,862</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">252,844</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">167,822</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

P0Y2M4D

P1Y

P0Y21D

P0Y6M3D

1.41

2.40

0.72

1.64

0.0476

0.0550

0.0017

0.0472

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Fair Value Measurements Using Significant Observable Inputs (Level 3)</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance - December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">686,856</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Addition of new derivatives recognized as debt discounts</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Addition of new derivatives recognized as loss on derivatives</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">459,854</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Settled on issuance of common stock</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(119,628</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">(Gain) loss on change in fair value of the derivative</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(207,010</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance - June 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">930,072</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

686856 110000 459854 -119628 -207010 930072

459854 28960 -207010 138862

252844

167822

7. STOCKHOLDERS’ EQUITY Preferred Stock On January 24, 2022, the Board of Directors of the Company’s, approved for an increase in the number of authorized shares of the Company’s preferred stock from 5,000,000 shares to 10,000,000 shares. The Company is authorized to issue 10,000,000 shares of $0.001 par value preferred stock, of which 4,000,000 have been designated as Series A Preferred Stock and 6,000,000 have been designated as Series B Preferred Stock. Series A Preferred Stock On February 6, 2020, the Company established its Series A Preferred Stock, par value $0.001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 4,000,000 shares of Series A Preferred Stock.The Company may use the Series A Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series A Preferred Stock have enhanced voting privileges under certain circumstances; the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 5:1 ratio. There are 1,600,000 shares of Series A shares issued as of the date of this filing. Series B Preferred Stock On January 24, 2022, the Company established its Series B Preferred Stock, par value $0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 6,000,000 shares of Series B Preferred Stock. The Company may use the Series B Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series B Preferred Stock have enhanced voting privileges (100:1); the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 10:1 ratio. As of the date of this filing, no shares of Series B Preferred Stock are issued and outstanding. Common Stock On March 7, 2023, the Company amended its articles of incorporation to increase its authorized common shares from 750,000,000 to 1,250,000,000; this increase will be effective March 27, 2023. As of June 30, 2023 and December 31, 2022, there were 576,474,023 and 252,544,765 shares of the Company’s common stock issued and outstanding, respectively. In addition, as of June 30, 2023, and December 31, 2022, there were 10,000 shares of the Company’s common stock issuable. Fiscal year 2023 During the six months ended June 30, 2023, the Company issued 323,919,258 shares of common stock valued at $204,093 for conversion of debt. Warrant On February 6, 2022, in conjunction with purchase of patent, the Company granted 1,000,000 shares for period of two years with exercise price of $0.006 per share. The fair value of granted shares at the issuance date was $5,429. The Company recorded warrant as additional paid-in-capital. The estimated fair values of the warrant are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">Year Ended</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Expected term</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">2.00 years</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected average volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">235</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected dividend yield</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.31</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table>

5000000

10000000

0.001

4000000

6000000

0.001

4000000 at a 5:1 ratio

1600000

0.0001

6000000

at a 10:1 ratio

750000000

1250000000

576474023

252544765

10000

323919258

204093

1000000

0.006

5429

P2Y

2.35

0.0131

8. RELATED PARTY TRANSACTIONS Notes payable – related party During the six months ended June 30, 2023 and 2022, the Company repaid notes payable to a related party and accrued interest of $0 and $30,000 and recognized interest of $168 and $363, respectively. As of June 30, 2023 and December 31, 2022, the Company recorded notes payable - related party of $8,444 and $8,444 and accrued interest of $1,214 and $1,047, respectively. The note is a 4% interest bearing promissory note that the term is 1 year. Due to related party During the six months ended June 30, 2023, Dr. Edward E. Jacobs, M.D., our CEO, advanced $51,044 for operating expenses. As of June 30, 2023 and December 31, 2022, the Company recorded due to related party of $52,846 and $1,802, respectively.

30000

168

363

8444 8444

1214

1047

0.04

51044 52846 1802

9. SUBSEQUENT EVENTS During July and early August, The REG A filed and as amended in November 2022 for 200,000,000 common shares at $0.001 were fully subscribed. This provides the Company with the liquidity to pursue further research into its lead products: Pluripain® , SleepEZ™ and Primilungs™ and move the Company’s testing, development and marketing programs forward. The Company is also in discussion with marketing specialists in expanding its footprint on the Amazon market place now that the RegA has been fully subscribed and provide the necessary funding for more intensive marketing efforts. Since the appointment of FCBTherapy as its exclusive Distributor, LiveStock impact is withdrawing from its own websale and is encouraged with the first initial wholesale order from FCBTherapy is over $9000 which is double the last 6 months gross sales.

200000000

0.001

9000 EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ð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
&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " 3@@M7')H)78P! #G% $P M@ $]L 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 *0 I !8+ #ZL0 " ! end XML 47 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 99 169 1 false 19 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://bioadaptives.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://bioadaptives.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Sheet http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Statements 4 false false R5.htm 000005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT Sheet http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT Statements 5 false false R6.htm 000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED) Sheet http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED) Statements 6 false false R7.htm 000007 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY Sheet http://bioadaptives.com/role/DescriptionOfBusinessAndHistory DESCRIPTION OF BUSINESS AND HISTORY Notes 7 false false R8.htm 000008 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES Sheet http://bioadaptives.com/role/SummaryOfSignificantPolicies SUMMARY OF SIGNIFICANT POLICIES Notes 8 false false R9.htm 000009 - Disclosure - GOING CONCERN Sheet http://bioadaptives.com/role/GoingConcern GOING CONCERN Notes 9 false false R10.htm 000010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Sheet http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilities ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Notes 10 false false R11.htm 000011 - Disclosure - CONVERTIBLE NOTES Notes http://bioadaptives.com/role/ConvertibleNotes CONVERTIBLE NOTES Notes 11 false false R12.htm 000012 - Disclosure - DERIVATIVE LIABILITIES Sheet http://bioadaptives.com/role/DerivativeLiabilities DERIVATIVE LIABILITIES Notes 12 false false R13.htm 000013 - Disclosure - STOCKHOLDERS EQUITY Sheet http://bioadaptives.com/role/StockholdersEquity STOCKHOLDERS EQUITY Notes 13 false false R14.htm 000014 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://bioadaptives.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 14 false false R15.htm 000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://bioadaptives.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 000016 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Policies) Sheet http://bioadaptives.com/role/SummaryOfSignificantPoliciesPolicies SUMMARY OF SIGNIFICANT POLICIES (Policies) Policies 16 false false R17.htm 000017 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Tables) Sheet http://bioadaptives.com/role/SummaryOfSignificantPoliciesTables SUMMARY OF SIGNIFICANT POLICIES (Tables) Tables http://bioadaptives.com/role/SummaryOfSignificantPolicies 17 false false R18.htm 000018 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Sheet http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilitiesTables ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Tables http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilities 18 false false R19.htm 000019 - Disclosure - CONVERTIBLE NOTES (Tables) Notes http://bioadaptives.com/role/ConvertibleNotesTables CONVERTIBLE NOTES (Tables) Tables http://bioadaptives.com/role/ConvertibleNotes 19 false false R20.htm 000020 - Disclosure - DERIVATIVE LIABILITIES (Tables) Sheet http://bioadaptives.com/role/DerivativeLiabilitiesTables DERIVATIVE LIABILITIES (Tables) Tables http://bioadaptives.com/role/DerivativeLiabilities 20 false false R21.htm 000021 - Disclosure - STOCKHOLDERS EQUITY (Tables) Sheet http://bioadaptives.com/role/StockholdersEquityTables STOCKHOLDERS EQUITY (Tables) Tables http://bioadaptives.com/role/StockholdersEquity 21 false false R22.htm 000022 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Details) Sheet http://bioadaptives.com/role/SummaryOfSignificantPoliciesDetails SUMMARY OF SIGNIFICANT POLICIES (Details) Details http://bioadaptives.com/role/SummaryOfSignificantPoliciesTables 22 false false R23.htm 000023 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://bioadaptives.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://bioadaptives.com/role/GoingConcern 23 false false R24.htm 000024 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Sheet http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilitiesDetails ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Details http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilitiesTables 24 false false R25.htm 000025 - Disclosure - CONVERTIBLE NOTES (Details) Notes http://bioadaptives.com/role/ConvertibleNotesDetails CONVERTIBLE NOTES (Details) Details http://bioadaptives.com/role/ConvertibleNotesTables 25 false false R26.htm 000026 - Disclosure - CONVERTIBLE NOTES (Details Narrative) Notes http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative CONVERTIBLE NOTES (Details Narrative) Details http://bioadaptives.com/role/ConvertibleNotesTables 26 false false R27.htm 000027 - Disclosure - DERIVATIVE LIABILITIES (Details) Sheet http://bioadaptives.com/role/DerivativeLiabilitiesDetails DERIVATIVE LIABILITIES (Details) Details http://bioadaptives.com/role/DerivativeLiabilitiesTables 27 false false R28.htm 000028 - Disclosure - DERIVATIVE LIABILITIES (Details 1) Sheet http://bioadaptives.com/role/DerivativeLiabilitiesDetails1 DERIVATIVE LIABILITIES (Details 1) Details http://bioadaptives.com/role/DerivativeLiabilitiesTables 28 false false R29.htm 000029 - Disclosure - DERIVATIVE LIABILITIES (Details 2) Sheet http://bioadaptives.com/role/DerivativeLiabilitiesDetails2 DERIVATIVE LIABILITIES (Details 2) Details http://bioadaptives.com/role/DerivativeLiabilitiesTables 29 false false R30.htm 000030 - Disclosure - STOCKHOLDERS EQUITY (Details) Sheet http://bioadaptives.com/role/StockholdersEquityDetails STOCKHOLDERS EQUITY (Details) Details http://bioadaptives.com/role/StockholdersEquityTables 30 false false R31.htm 000031 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative) Sheet http://bioadaptives.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS EQUITY (Details Narrative) Details http://bioadaptives.com/role/StockholdersEquityTables 31 false false R32.htm 000032 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://bioadaptives.com/role/RelatedPartyTransactions 32 false false R33.htm 000033 - Disclosure - SUBSEQUENT EVENT (Details Narrative) Sheet http://bioadaptives.com/role/SubsequentEventDetailsNarrative SUBSEQUENT EVENT (Details Narrative) Details http://bioadaptives.com/role/SubsequentEvents 33 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 21 fact(s) appearing in ix:hidden were eligible for transformation: bdpt:CommonStockCapitalSharesReservedForFutureIssuance1, dei:DocumentQuarterlyReport, dei:DocumentTransitionReport, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesOutstanding, us-gaap:DebtInstrumentTerm, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding - bdpt_10q.htm 1 bdpt_10q.htm bdpt-20230630.xsd bdpt-20230630_cal.xml bdpt-20230630_def.xml bdpt-20230630_lab.xml bdpt-20230630_pre.xml bdpt_ex311.htm bdpt_ex312.htm bdpt_ex321.htm bdpt_ex322.htm bdpt_10qimg1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 52 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bdpt_10q.htm": { "axisCustom": 0, "axisStandard": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 377, "http://xbrl.sec.gov/dei/2023": 27 }, "contextCount": 99, "dts": { "calculationLink": { "local": [ "bdpt-20230630_cal.xml" ] }, "definitionLink": { "local": [ "bdpt-20230630_def.xml" ] }, "inline": { "local": [ "bdpt_10q.htm" ] }, "labelLink": { "local": [ "bdpt-20230630_lab.xml" ] }, "presentationLink": { "local": [ "bdpt-20230630_pre.xml" ] }, "schema": { "local": [ "bdpt-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 233, "entityCount": 1, "hidden": { "http://bioadaptives.com/20230630": 1, "http://fasb.org/us-gaap/2023": 18, "http://xbrl.sec.gov/dei/2023": 7, "total": 26 }, "keyCustom": 30, "keyStandard": 139, "memberCustom": 8, "memberStandard": 11, "nsprefix": "bdpt", "nsuri": "http://bioadaptives.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "strong", "span", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://bioadaptives.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "strong", "span", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "menuCat": "Notes", "order": "10", "role": "http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilities", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - CONVERTIBLE NOTES", "menuCat": "Notes", "order": "11", "role": "http://bioadaptives.com/role/ConvertibleNotes", "shortName": "CONVERTIBLE NOTES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - DERIVATIVE LIABILITIES", "menuCat": "Notes", "order": "12", "role": "http://bioadaptives.com/role/DerivativeLiabilities", "shortName": "DERIVATIVE LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - STOCKHOLDERS EQUITY", "menuCat": "Notes", "order": "13", "role": "http://bioadaptives.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "14", "role": "http://bioadaptives.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "15", "role": "http://bioadaptives.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Policies)", "menuCat": "Policies", "order": "16", "role": "http://bioadaptives.com/role/SummaryOfSignificantPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Tables)", "menuCat": "Tables", "order": "17", "role": "http://bioadaptives.com/role/SummaryOfSignificantPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "menuCat": "Tables", "order": "18", "role": "http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilitiesTables", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - CONVERTIBLE NOTES (Tables)", "menuCat": "Tables", "order": "19", "role": "http://bioadaptives.com/role/ConvertibleNotesTables", "shortName": "CONVERTIBLE NOTES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://bioadaptives.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - DERIVATIVE LIABILITIES (Tables)", "menuCat": "Tables", "order": "20", "role": "http://bioadaptives.com/role/DerivativeLiabilitiesTables", "shortName": "DERIVATIVE LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - STOCKHOLDERS EQUITY (Tables)", "menuCat": "Tables", "order": "21", "role": "http://bioadaptives.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Details)", "menuCat": "Details", "order": "22", "role": "http://bioadaptives.com/role/SummaryOfSignificantPoliciesDetails", "shortName": "SUMMARY OF SIGNIFICANT POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member", "decimals": "0", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bdpt:RetainedEarningAccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - GOING CONCERN (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://bioadaptives.com/role/GoingConcernDetailsNarrative", "shortName": "GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bdpt:RetainedEarningAccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "menuCat": "Details", "order": "24", "role": "http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bdpt:TotalConvertibleNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - CONVERTIBLE NOTES (Details)", "menuCat": "Details", "order": "25", "role": "http://bioadaptives.com/role/ConvertibleNotesDetails", "shortName": "CONVERTIBLE NOTES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bdpt:TotalConvertibleNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bdpt:DebtDiscount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - CONVERTIBLE NOTES (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative", "shortName": "CONVERTIBLE NOTES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bdpt:DebtDiscount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - DERIVATIVE LIABILITIES (Details)", "menuCat": "Details", "order": "27", "role": "http://bioadaptives.com/role/DerivativeLiabilitiesDetails", "shortName": "DERIVATIVE LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bdpt:BeginningBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - DERIVATIVE LIABILITIES (Details 1)", "menuCat": "Details", "order": "28", "role": "http://bioadaptives.com/role/DerivativeLiabilitiesDetails1", "shortName": "DERIVATIVE LIABILITIES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bdpt:BeginningBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bdpt:LossOnDerivativeInstrumentsRelatedConvertibleNotes", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - DERIVATIVE LIABILITIES (Details 2)", "menuCat": "Details", "order": "29", "role": "http://bioadaptives.com/role/DerivativeLiabilitiesDetails2", "shortName": "DERIVATIVE LIABILITIES (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "bdpt:LossOnDerivativeInstrumentsRelatedConvertibleNotes", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - STOCKHOLDERS EQUITY (Details)", "menuCat": "Details", "order": "30", "role": "http://bioadaptives.com/role/StockholdersEquityDetails", "shortName": "STOCKHOLDERS EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2022-01-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)", "menuCat": "Details", "order": "31", "role": "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2022-01-24", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - SUBSEQUENT EVENT (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://bioadaptives.com/role/SubsequentEventDetailsNarrative", "shortName": "SUBSEQUENT EVENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2022-11-30", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)", "menuCat": "Statements", "order": "4", "role": "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "AsOf2021-12-31_bdpt_SeriesAPreferredStocksMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT", "menuCat": "Statements", "order": "5", "role": "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit", "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2022-01-01to2022-03-31_us-gaap_CommonStockMember", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED)", "menuCat": "Statements", "order": "6", "role": "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY", "menuCat": "Notes", "order": "7", "role": "http://bioadaptives.com/role/DescriptionOfBusinessAndHistory", "shortName": "DESCRIPTION OF BUSINESS AND HISTORY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES", "menuCat": "Notes", "order": "8", "role": "http://bioadaptives.com/role/SummaryOfSignificantPolicies", "shortName": "SUMMARY OF SIGNIFICANT POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - GOING CONCERN", "menuCat": "Notes", "order": "9", "role": "http://bioadaptives.com/role/GoingConcern", "shortName": "GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "bdpt_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 19, "tag": { "bdpt_AccruedInterestCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accrued interest" } } }, "localname": "AccruedInterestCurrent", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bdpt_AdditionOfNewDerivativesRecognizedAsDebtDiscounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Addition of new derivatives recognized as debt discounts" } } }, "localname": "AdditionOfNewDerivativesRecognizedAsDebtDiscounts", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "bdpt_AdditionOfNewDerivativesRecognizedAsLossOnDerivatives": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Addition of new derivatives recognized as loss on derivatives" } } }, "localname": "AdditionOfNewDerivativesRecognizedAsLossOnDerivatives", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "bdpt_AdvancesToRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Advances to related party" } } }, "localname": "AdvancesToRelatedParty", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bdpt_AmortizationOfDebtDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Amortization of debt discount]", "verboseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscount", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bdpt_AmountReceiveFromInitialWholesaleOrder": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Amount receive from initial wholesale order" } } }, "localname": "AmountReceiveFromInitialWholesaleOrder", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bdpt_BasicAndDilutedEarningPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and Diluted" } } }, "localname": "BasicAndDilutedEarningPerShare", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "perShareItemType" }, "bdpt_BeginningBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Beginnig Balance" } } }, "localname": "BeginningBalance", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "bdpt_CommonStockCapitalSharesReservedForFutureIssuance1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, shares issuable", "verboseLabel": "Common stock, shares issuable" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance1", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bdpt_CommonStockSharesGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock, shares granted" } } }, "localname": "CommonStockSharesGranted", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bdpt_CommonStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stocks [Member]" } } }, "localname": "CommonStocksMember", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "bdpt_ConversionCommonRights": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion common rights" } } }, "localname": "ConversionCommonRights", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "bdpt_ConvertibleNotesAccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Accrued interest]", "verboseLabel": "Accrued interest" } } }, "localname": "ConvertibleNotesAccruedInterest", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bdpt_ConvertibleNotesPayableBeforeUnamortizedDebtDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Total convertible notes payable]", "verboseLabel": "Total convertible notes payable" } } }, "localname": "ConvertibleNotesPayableBeforeUnamortizedDebtDiscount", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "bdpt_ConvertibleNotesabstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONVERTIBLE NOTES" } } }, "localname": "ConvertibleNotesabstract", "nsuri": "http://bioadaptives.com/20230630", "xbrltype": "stringItemType" }, "bdpt_ConvertibleSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible shares of common stock" } } }, "localname": "ConvertibleSharesOfCommonStock", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bdpt_DebtDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Debt discount" } } }, "localname": "DebtDiscount", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bdpt_DebtsForgivenessRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debts forgiveness - related party", "verboseLabel": "Debts forgiveness - related party" } } }, "localname": "DebtsForgivenessRelatedParty", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit", "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "bdpt_DerivativeLossOnDerivative1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Derivative loss" } } }, "localname": "DerivativeLossOnDerivative1", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bdpt_DrEdwardeJacobsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dr. Edward E. Jacobs [Member]" } } }, "localname": "DrEdwardeJacobsMember", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "bdpt_DueToRelatedParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Due to related parties" } } }, "localname": "DueToRelatedParties", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bdpt_EarningsPerShareBasicsAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Common Share:" } } }, "localname": "EarningsPerShareBasicsAndDilutedAbstract", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "bdpt_EndingBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Ending Balance" } } }, "localname": "EndingBalance", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "bdpt_GainLossOnChangeInFairValueOfTheDerivativeLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Loss on change in fair value of the derivative", "verboseLabel": "(Gain) loss on change in fair value of the derivative liabilities" } } }, "localname": "GainLossOnChangeInFairValueOfTheDerivativeLiabilities", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails1", "http://bioadaptives.com/role/DerivativeLiabilitiesDetails2" ], "xbrltype": "monetaryItemType" }, "bdpt_IssuedFiscalYearTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issued fiscal year 2023 [Member]" } } }, "localname": "IssuedFiscalYearTwoThousandTwentyThreeMember", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "bdpt_IssuedFiscalYearTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issued fiscal year 2022 [Member]" } } }, "localname": "IssuedFiscalYearTwoThousandTwentyTwoMember", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "bdpt_LossOnDerivativeInstrumentsRelatedConvertibleNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Day one loss due to derivative liabilities on convertible notes" } } }, "localname": "LossOnDerivativeInstrumentsRelatedConvertibleNotes", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails2" ], "xbrltype": "monetaryItemType" }, "bdpt_NotesPayableRelatedPartiesClassifiedAsCurrent": { "auth_ref": [], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Note payable - related party" } } }, "localname": "NotesPayableRelatedPartiesClassifiedAsCurrent", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "bdpt_NotesPayableToRelatedPartiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Notes payable- related party noncurrent" } } }, "localname": "NotesPayableToRelatedPartiesNoncurrent", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bdpt_OriginatedInAprilTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "originated in April 2018 [Member]" } } }, "localname": "OriginatedInAprilTwoThousandEighteenMember", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "bdpt_OriginatedInJuneTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Originated in June 2018 [Member]" } } }, "localname": "OriginatedInJuneTwoThousandEighteenMember", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "bdpt_OriginatedInOctoberTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Originated in October 2018 [Member]" } } }, "localname": "OriginatedInOctoberTwoThousandEighteenMember", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "bdpt_PreferredStockShareAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Preferred stock, shares authorized]", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockShareAuthorized", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "bdpt_ProceedsFromConvertibleNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from Convertible notes" } } }, "localname": "ProceedsFromConvertibleNotes", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bdpt_RetainedEarningAccumulatedDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Accumulated deficit]", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningAccumulatedDeficit", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "bdpt_SeriesAPreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Preferred Stocks" } } }, "localname": "SeriesAPreferredStocksMember", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "bdpt_SettledOnIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Settled on issuance of common stock]", "verboseLabel": "Settled on issuance of common stock" } } }, "localname": "SettledOnIssuanceOfCommonStock", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "monetaryItemType" }, "bdpt_TotalConvertibleNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total convertible notes payable" } } }, "localname": "TotalConvertibleNotesPayable", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "bdpt_UnrealizedGainAndLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments": { "auth_ref": [], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Unrealized (gain) loss on investments in marketable securities]", "negatedLabel": "Unrealized (gain) loss on investments in marketable securities" } } }, "localname": "UnrealizedGainAndLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "bdpt_ValueAssignedOfDerivativesLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Value Assigned of derivatives liabilities" } } }, "localname": "ValueAssignedOfDerivativesLiabilities", "nsuri": "http://bioadaptives.com/20230630", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://bioadaptives.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r220", "r272", "r295", "r323", "r324", "r382", "r383", "r384", "r385", "r386", "r393", "r394", "r399", "r404", "r408", "r412", "r445", "r480", "r481", "r482", "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r220", "r272", "r295", "r323", "r324", "r382", "r383", "r384", "r385", "r386", "r393", "r394", "r399", "r404", "r408", "r412", "r445", "r480", "r481", "r482", "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r166", "r167", "r168", "r169", "r212", "r220", "r222", "r223", "r224", "r271", "r272", "r295", "r323", "r324", "r382", "r383", "r384", "r385", "r386", "r393", "r394", "r399", "r404", "r408", "r412", "r415", "r441", "r445", "r481", "r482", "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "label": "Range Axis" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r166", "r167", "r168", "r169", "r212", "r220", "r222", "r223", "r224", "r271", "r272", "r295", "r323", "r324", "r382", "r383", "r384", "r385", "r386", "r393", "r394", "r399", "r404", "r408", "r412", "r415", "r441", "r445", "r481", "r482", "r483", "r484", "r485" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued liabilities", "verboseLabel": "Accounts Payable And Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r10", "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities", "verboseLabel": "Accrued interest" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r15", "r396" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued salary" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r57", "r411", "r489" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r225", "r226", "r227", "r311", "r436", "r437", "r438", "r475", "r493" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AirlineRelatedInventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENT (Details Narrative)" } } }, "localname": "AirlineRelatedInventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r4", "r48", "r67", "r191" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r4", "r37", "r38" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of license and patent", "verboseLabel": "Amortization of license and patent" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited", "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r84", "r101", "r124", "r148", "r154", "r158", "r163", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r231", "r235", "r251", "r287", "r344", "r411", "r423", "r443", "r444", "r478" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r99", "r106", "r124", "r163", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r231", "r235", "r251", "r411", "r443", "r444", "r478" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date Axis" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r52", "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "1. DESCRIPTION OF BUSINESS AND HISTORY" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/DescriptionOfBusinessAndHistory" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r24", "r69", "r120" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets", "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r1", "r69" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r96", "r102", "r103", "r104", "r124", "r139", "r140", "r143", "r144", "r146", "r147", "r163", "r170", "r172", "r173", "r174", "r177", "r178", "r197", "r198", "r200", "r203", "r209", "r251", "r302", "r303", "r304", "r305", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r332", "r353", "r374", "r387", "r388", "r389", "r390", "r391", "r428", "r434", "r439" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets", "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r436", "r437", "r475", "r488", "r493" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, shares par value", "verboseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r56", "r332" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative", "http://bioadaptives.com/role/SubsequentEventDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r56", "r332", "r350", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r56", "r289", "r411" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock ($.0001 par value, 1,250,000,000 shares authorized; 576,474,023 and 252,554,765 shares issued and outstanding, and 10,000 issuable, respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r26", "r27", "r28" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Issuance of common stock for conversion of debt" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r26", "r27", "r28" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares Issued of common stock" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Schedule of Convertible Notes" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r19" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Long-term convertible notes" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r9", "r86", "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Total convertible notes" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r15" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Current portion of convertible notes - net of discount of $42,512 and $7,647", "verboseLabel": "Less: current portion of convertible notes" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets", "http://bioadaptives.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r54", "r85" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]", "verboseLabel": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails", "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r65", "r124", "r163", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r251", "r443" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r26", "r28" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt instrument converted amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r26", "r28" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt instrument converted amount shares issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Description of conversion price" } } }, "localname": "DebtConversionDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r26", "r28" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of debt" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionOriginalDebtInterestRateOfDebt": { "auth_ref": [ "r26", "r28" ], "lang": { "en-us": { "role": { "documentation": "The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Annual interest rates" } } }, "localname": "DebtConversionOriginalDebtInterestRateOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r76", "r122", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r187", "r192", "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "5. CONVERTIBLE NOTES" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.", "label": "Principal amount of convertible notes" } } }, "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "auth_ref": [ "r18", "r40", "r78", "r79" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for debt instrument.", "label": "Debt Instrument, Convertible, Terms of Conversion Feature" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r17", "r49", "r189" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Rate of interest" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Convertible debt term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r48", "r51", "r446" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Convertible notes payable current, discount", "negatedLabel": "Less: Unamortized debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r474" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 9.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Change in fair value of derivative liabilities" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DERIVATIVE LIABILITIES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r82", "r238", "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "6. DERIVATIVE LIABILITIES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r107" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liabilities", "verboseLabel": "Derivative liabilities" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets", "http://bioadaptives.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r7", "r41", "r42", "r43", "r46", "r125" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r31", "r32" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings (loss) per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r6", "r97", "r110", "r111", "r112", "r126", "r127", "r128", "r130", "r135", "r137", "r145", "r164", "r165", "r211", "r225", "r226", "r227", "r228", "r229", "r239", "r240", "r241", "r242", "r243", "r244", "r247", "r252", "r253", "r254", "r255", "r256", "r257", "r259", "r296", "r297", "r298", "r311", "r374" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r0", "r4" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "[Fair Value Adjustment of Warrants]", "terseLabel": "Fair value of shares granted", "verboseLabel": "Change in fair value of derivative liabilities" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited", "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r186", "r213", "r214", "r215", "r216", "r217", "r218", "r250", "r268", "r269", "r270", "r400", "r401", "r405", "r406", "r407" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r186", "r213", "r218", "r250", "r268", "r405", "r406", "r407" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r186", "r213", "r218", "r250", "r269", "r400", "r401", "r405", "r406", "r407" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r186", "r213", "r214", "r215", "r216", "r217", "r218", "r250", "r270", "r400", "r401", "r405", "r406", "r407" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r47", "r83" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Schedule of Estimated Fair Values of Liabilities Measured on Recurring Basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r186", "r213", "r214", "r215", "r216", "r217", "r218", "r268", "r269", "r270", "r400", "r401", "r405", "r406", "r407" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r5", "r8" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Financial Instruments and Fair Value Measurements" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Aggregate (gain) loss on derivatives" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails2" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r66", "r355" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r64", "r124", "r148", "r153", "r157", "r159", "r163", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r251", "r398", "r443" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "[Gross Profit]", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairedFinancingReceivableUnpaidPrincipalBalance": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unpaid principal balance of impaired financing receivables with related allowance for credit losses and without related allowance for credit losses.", "label": "Unpaid principal amount" } } }, "localname": "ImpairedFinancingReceivableUnpaidPrincipalBalance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r81", "r124", "r129", "r148", "r153", "r157", "r159", "r163", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r248", "r251", "r292", "r398", "r443" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "[Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest]", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r3" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "[Increase (Decrease) in Accounts Payable and Accrued Liabilities]", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r3" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Due to related party" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r3" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Inventories]", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedLicenseAgreements": { "auth_ref": [ "r75" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit.", "label": "License and patent, net" } } }, "localname": "IndefiniteLivedLicenseAgreements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r50", "r89", "r113", "r151", "r258", "r359", "r421", "r490" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 8.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r67", "r190", "r195", "r402", "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest expenses" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "auth_ref": [ "r138", "r141", "r144" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.", "label": "Accrued interest of convertible notes" } } }, "localname": "InterestOnConvertibleDebtNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r433" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest amount" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r115", "r118", "r119" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes payable - accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r105", "r395", "r411" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r124", "r163", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r232", "r235", "r236", "r251", "r331", "r397", "r423", "r443", "r478", "r479" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r61", "r87", "r291", "r411", "r435", "r440", "r476" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r16", "r100", "r124", "r163", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r232", "r235", "r236", "r251", "r411", "r443", "r478", "r479" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r429" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable securities", "verboseLabel": "Equity Securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets", "http://bioadaptives.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r63" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 7.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Unrealized gain (loss) on marketable securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r117" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 15.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net Cash Provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r69", "r70", "r71" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 14.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net Cash Used in Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r62", "r71", "r88", "r98", "r108", "r109", "r112", "r124", "r129", "r131", "r132", "r133", "r134", "r136", "r137", "r142", "r148", "r153", "r157", "r159", "r163", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r248", "r251", "r294", "r352", "r372", "r373", "r398", "r421", "r443" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "totalLabel": "Net Loss", "verboseLabel": "Net loss for the period" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit", "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CASH INVESTING AND FINANCING ACTIVITIES" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 11.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DESCRIPTION OF BUSINESS AND HISTORY" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income (Expense)" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 12.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "[Other Nonoperating Income (Expense)]", "totalLabel": "Total Other Expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r55", "r197" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, shares par value", "verboseLabel": "Preferred stock, shares par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r55", "r332" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r55", "r197" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued", "verboseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r55", "r332", "r350", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r55", "r288", "r411" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, ($.0001 par value, 10,000,000 shares authorized;" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r22" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from convertible notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r2" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Settled on issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r22" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceed from related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r421", "r491", "r492" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r98", "r108", "r109", "r116", "r124", "r129", "r136", "r137", "r148", "r153", "r157", "r159", "r163", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r230", "r233", "r234", "r248", "r251", "r286", "r293", "r310", "r352", "r372", "r373", "r398", "r409", "r410", "r422", "r432", "r443" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "negatedLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r219", "r263", "r264", "r326", "r327", "r328", "r329", "r330", "r349", "r351", "r381" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r219", "r263", "r264", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r326", "r327", "r328", "r329", "r330", "r349", "r351", "r381", "r477" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r260", "r261", "r262", "r264", "r265", "r307", "r308", "r309", "r356", "r357", "r358", "r378", "r380" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "8. RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r23" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "[Repayments of Notes Payable]", "negatedLabel": "Repayment of notes payable - related party" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r23" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "[Repayments of Related Party Debt]", "negatedLabel": "Repayment to related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "[Repayments of Short-Term Debt]", "verboseLabel": "Repayment of notes payable - related party" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r58", "r80", "r290", "r299", "r300", "r306", "r333", "r411" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r97", "r126", "r127", "r128", "r130", "r135", "r137", "r164", "r165", "r225", "r226", "r227", "r228", "r229", "r239", "r241", "r242", "r244", "r247", "r296", "r298", "r311", "r493" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r114", "r124", "r149", "r150", "r152", "r155", "r156", "r160", "r161", "r162", "r163", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r251", "r286", "r443" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GOING CONCERN" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/AccountsPayableAndAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r44", "r45", "r237" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Schedule of (gain) loss on Derivatives" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "Summary of Changes in Derivative Liabilities" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value of Measurements of Assets on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/SummaryOfSignificantPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Estimated Fair Values of Warrant Measured on Recurring Basis" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeparateAccountLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in liability for separate account.", "label": "Derivative liability recognized as debt discount" } } }, "localname": "SeparateAccountLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r430", "r431", "r447" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets", "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r430", "r431", "r447" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets", "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate]", "verboseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected average volatility", "verboseLabel": "Expected average volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails", "http://bioadaptives.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate", "verboseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails", "http://bioadaptives.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.", "label": "Expected dividend yield" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "[Share-Based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term]", "verboseLabel": "Expected term" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short Term Debt Type Axis" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails", "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConvertibleNotesDetails", "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r72", "r121" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "2. SUMMARY OF SIGNIFICANT POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/SummaryOfSignificantPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandardProductWarrantyAccrualAdditionsFromBusinessAcquisition": { "auth_ref": [ "r442" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the standard product warranty accrual from a business acquisition. Excludes extended product warranties.", "label": "Warrant issued for acquisition of patent", "verboseLabel": "Warrant issued for Patent's acquisition" } } }, "localname": "StandardProductWarrantyAccrualAdditionsFromBusinessAcquisition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit", "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r96", "r102", "r103", "r104", "r124", "r139", "r140", "r143", "r144", "r146", "r147", "r163", "r170", "r172", "r173", "r174", "r177", "r178", "r197", "r198", "r200", "r203", "r209", "r251", "r302", "r303", "r304", "r305", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r332", "r353", "r374", "r387", "r388", "r389", "r390", "r391", "r428", "r434", "r439" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets", "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r6", "r21", "r97", "r110", "r111", "r112", "r126", "r127", "r128", "r130", "r135", "r137", "r145", "r164", "r165", "r211", "r225", "r226", "r227", "r228", "r229", "r239", "r240", "r241", "r242", "r243", "r244", "r247", "r252", "r253", "r254", "r255", "r256", "r257", "r259", "r296", "r297", "r298", "r311", "r374" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r126", "r127", "r128", "r145", "r273", "r301", "r322", "r325", "r326", "r327", "r328", "r329", "r330", "r332", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r354", "r355", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r374", "r416" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets", "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit", "http://bioadaptives.com/role/ConvertibleNotesDetails", "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative", "http://bioadaptives.com/role/DerivativeLiabilitiesDetails", "http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative", "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative", "http://bioadaptives.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r126", "r127", "r128", "r145", "r273", "r301", "r322", "r325", "r326", "r327", "r328", "r329", "r330", "r332", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r346", "r347", "r348", "r349", "r351", "r354", "r355", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r374", "r416" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets", "http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical", "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit", "http://bioadaptives.com/role/ConvertibleNotesDetails", "http://bioadaptives.com/role/ConvertibleNotesDetailsNarrative", "http://bioadaptives.com/role/DerivativeLiabilitiesDetails", "http://bioadaptives.com/role/RelatedPartyTransactionsDetailsNarrative", "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative", "http://bioadaptives.com/role/SummaryOfSignificantPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r6", "r20", "r40", "r80", "r188" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Common stock issued for conversion of debt, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r6", "r21", "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Common stock issued for conversion of debt, amount" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionExercisePriceIncrease": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.", "label": "Exercise price" } } }, "localname": "StockOptionExercisePriceIncrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r56", "r59", "r60", "r74", "r334", "r350", "r375", "r376", "r411", "r423", "r435", "r440", "r476", "r493" ], "calculation": { "http://bioadaptives.com/role/ConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total Stockholders' Deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets", "http://bioadaptives.com/role/ConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS EQUITY" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r77", "r123", "r196", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r211", "r246", "r377", "r379", "r392" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "7. STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r266", "r267" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "9. SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "3. GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r33", "r34", "r35", "r92", "r93", "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/SummaryOfSignificantPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r29", "r30" ], "lang": { "en-us": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "[Weighted Average Number of Shares Issued, Basic]", "verboseLabel": "Basic and Diluted" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Common Shares Outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r424": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r425": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r426": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r427": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org//205-40/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org//815/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 53 0001640334-23-001531-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001640334-23-001531-xbrl.zip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end

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 11, 2023		/s/ Edward E. Jacobs, Jr
		Edward E. Jacobs, Jr
		Chief Executive Officer
		(Principal Executive Officer)